Catheter Precision (VTAK) 10-Q 13 Nov 24 2024 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2024	Nov. 08, 2024
Cover [Abstract]
Entity Registrant Name	Catheter Precision, Inc.
Entity Central Index Key	0001716621
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Sep. 30, 2024
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Entity Common Stock Shares Outstanding		8,004,633
Entity File Number	001-38677
Entity Incorporation State Country Code	DE
Entity Tax Identification Number	38-3661826
Entity Address Address Line 1	1670 Highway 160 West
Entity Address Address Line 2	Suite 205
Entity Address City Or Town	Fort Mill
Entity Address State Or Province	SC
Entity Address Postal Zip Code	29708
City Area Code	973
Local Phone Number	691-2000
Security 12b Title	Common stock, par value $0.0001 per share
Trading Symbol	VTAK
Security Exchange Name	NYSE
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current Assets
Cash and cash equivalents	$ 1,268	$ 3,565
Accounts receivable	107	137
Inventories	32	44
Prepaid expenses and other current assets	307	415
Total current assets	1,714	4,161
Property and equipment, net	111	70
Operating lease right-of-use assets, net	127	179
Intangible assets, net	24,785	26,318
Other non-current assets	8	8
TOTAL ASSETS	26,745	30,736
Current Liabilities
Accounts payable	708	464
Accrued expenses	1,497	1,733
Notes payable	249	184
Interest payable to related parties	16	0
Current portion of royalties payable	17	0
Current portion of operating lease liabilities	99	91
Total current liabilities	2,586	2,472
Royalties payable	9,797	6,974
Notes payable due to related parties	1,500	0
Operating lease liabilities	36	97
Total liabilities	13,919	9,543
Stockholders' Equity
Common stock, $0.0001 par value, 30,000,000 shares authorized; 3,452,652 and 702,662 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively	0	0
Additional paid-in capital	299,550	296,902
Accumulated deficit	(286,724)	(275,709)
Total stockholders' equity	12,826	21,193
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	26,745	30,736
Series A convertible preferred stocks [Member]
Stockholders' Equity
Preferred Stock, value	0	0
Series X convertible preferred stocks [Member]
Stockholders' Equity
Preferred Stock, value	$ 0	$ 0

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Common stock, shares authorized	30,000,000	300,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares issued	3,452,652	702,662
Common stock, shares outstanding	3,452,652	702,662
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, par value	$ 0.0001	$ 0.0001
Series A convertible preferred stock [Member]
Preferred stock, shares designated	7,203	7,203
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares issued	0	4,578
Preferred stock, shares Outstanding	0	4,578
Series X Convertible Preferred Stock [Member]
Preferred stock, shares designated	15,404	15,404
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares issued	12,656	12,656
Preferred stock, shares Outstanding	12,656	12,656

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Condensed Consolidated Statements of Operations (Unaudited)
Revenue	$ 96	$ 133	$ 271	$ 314
Cost of revenues	10	6	31	23
Gross profit	86	127	240	291
Operating expenses
Loss on impairment of goodwill	0	0	0	60,934
Selling, general and administrative	2,882	2,745	8,251	14,393
Research and development	63	112	181	486
Total operating expenses	2,945	2,857	8,432	75,813
Operating loss	(2,859)	(2,730)	(8,192)	(75,522)
Other income (expense), net
Interest income	7	87	47	293
Interest expense	(32)	0	(40)	(18)
Other expense, net	(3)	0	(7)	11
Change in fair value of royalties payable	(1,233)	716	(2,823)	5,333
Total other income (expense), net	(1,261)	803	(2,823)	5,619
Net loss	(4,120)	(1,927)	(11,015)	(69,903)
Deemed dividend - warrant inducement offer	0	0	0	(800)
Net loss attributable to common stockholders	$ (4,120)	$ (1,927)	$ (11,015)	$ (70,703)
Net loss per share attributable to common stockholders, basic and diluted	$ (2.01)	$ (2.83)	$ (9.28)	$ (141.96)
Weighted average common shares used in computing net loss per share, basic and diluted	2,050,947	680,596	1,187,100	498,054

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Series X Convertible Preferred Stock [Member]	Series A Convertible Preferred Stock	Common Stock	Additional Paid-In Capital	Retained Earnings (Accumulated Deficit)
Balance, shares at Dec. 31, 2022		0	0	216,127
Balance, amount at Dec. 31, 2022	$ 9,260	$ 0	$ 0	$ 0	$ 214,397	$ (205,137)
Common stock issued upon the exercise of options, shares				30,175
Common stock issued upon the exercise of options, amount	179	0	0	$ 0	179	0
Restricted stock awards cancelled, shares				(36)
Restricted stock awards cancelled, amount	0	0	0	$ 0	0	0
Stock-based compensation	1,394	$ 0	0	0	1,394	0
Issuance of Series X Convertible Preferred Stock in merger, shares		14,650
Issuance of Series X Convertible Preferred Stock in merger, amount	82,925	$ 0	0	$ 0	82,925	0
Conversion of Series X Convertible Preferred Stock, shares		(1,975)		197,491
Conversion of Series X Convertible Preferred Stock, amount	0	$ 0	$ 0	$ 0	0	0
Issuance of Series A Convertible Preferred Stock in connection with private placement, net, shares			7,203	49,791
Issuance of Series A Convertible Preferred Stock in connection with private placement, net, amount	7,360	0	$ 0	$ 0	7,360	0
Warrants exercised (see Note 13), shares				33,161
Warrants exercised (see Note 13), amount	1,145	0	0	$ 0	1,145	0
Net loss	(66,400)	$ 0	$ 0	$ 0	0	(66,400)
Balance, shares at Mar. 31, 2023		12,675	7,203	526,709
Balance, amount at Mar. 31, 2023	35,863	$ 0	$ 0	$ 0	307,400	(271,537)
Balance, shares at Dec. 31, 2022		0	0	216,127
Balance, amount at Dec. 31, 2022	9,260	$ 0	$ 0	$ 0	214,397	(205,137)
Net loss	(69,903)
Balance, shares at Sep. 30, 2023		12,675	4,578	700,800
Balance, amount at Sep. 30, 2023	21,867	$ 0	$ 0	$ 1	296,906	(275,040)
Balance, shares at Mar. 31, 2023		12,675	7,203	526,709
Balance, amount at Mar. 31, 2023	35,863	$ 0	$ 0	$ 0	307,400	(271,537)
Common stock issued upon the exercise of options, shares				10,058
Common stock issued upon the exercise of options, amount	59	0	0	$ 0	59	0
Net loss	(1,576)	0	0	0	0	(1,576)
Adjustment of fair value of Series X Convertible Preferred Stock in merger	(10,381)	0	0	0	(10,381)	0
Adjustment of fair value of stock-based compensation related to merger	(174)	$ 0	$ 0	$ 0	(174)	0
Balance, shares at Jun. 30, 2023		12,675	7,203	536,767
Balance, amount at Jun. 30, 2023	23,791	$ 0	$ 0	$ 0	296,904	(273,113)
Stock-based compensation	2	0	0	0	2	0
Net loss	(1,927)	0	$ 0	$ 0	0	(1,927)
Conversion of Series A Convertible Preferred Stock, shares			2,625	164,033
Conversion of Series A Convertible Preferred Stock, amount	1	$ 0	$ 0	$ 1	0	0
Balance, shares at Sep. 30, 2023		12,675	4,578	700,800
Balance, amount at Sep. 30, 2023	21,867	$ 0	$ 0	$ 1	296,906	(275,040)
Balance, shares at Dec. 31, 2023		12,656	4,578	702,662
Balance, amount at Dec. 31, 2023	21,193	$ 0	$ 0	$ 0	296,902	(275,709)
Stock-based compensation	6	0	0	0	6	0
Net loss	(2,675)	0	$ 0	$ 0	0	(2,675)
Conversion of Series A Convertible Preferred Stock, shares			875	54,678
Conversion of Series A Convertible Preferred Stock, amount	0	$ 0	$ 0	$ 0	0	0
Balance, shares at Mar. 31, 2024		12,656	3,703	757,340
Balance, amount at Mar. 31, 2024	18,524	$ 0	$ 0	$ 0	296,908	(278,384)
Balance, shares at Dec. 31, 2023		12,656	4,578	702,662
Balance, amount at Dec. 31, 2023	$ 21,193	$ 0	$ 0	$ 0	296,902	(275,709)
Common stock issued upon the exercise of options, shares	0
Net loss	$ (11,015)
Balance, shares at Sep. 30, 2024		12,656	0	3,452,652
Balance, amount at Sep. 30, 2024	12,826	$ 0	$ 0	$ 0	299,550	(286,724)
Balance, shares at Mar. 31, 2024		12,656	3,703	757,340
Balance, amount at Mar. 31, 2024	18,524	$ 0	$ 0	$ 0	296,908	(278,384)
Stock-based compensation	13	0	0	0	13	0
Net loss	(4,220)	$ 0	$ 0	$ 0	0	(4,220)
Balance, shares at Jun. 30, 2024		12,656	3,703	757,340
Balance, amount at Jun. 30, 2024	14,317	$ 0	$ 0	$ 0	296,921	(282,604)
Stock-based compensation	17	0	0	0	17	0
Net loss	(4,120)	0	$ 0	$ 0	0	(4,120)
Conversion of Series A Convertible Preferred Stock, shares			3,703	231,412
Conversion of Series A Convertible Preferred Stock, amount	0	0	$ 0	$ 0	0	0
Issuance of common stock and other equity-classified contracts from September 2024 Public Offering, net of issuance costs, shares				805,900
Issuance of common stock and other equity-classified contracts from September 2024 Public Offering, net of issuance costs, amount	2,612	0	0	$ 0	2,612	0
Issuance of common stock upon exercise of Pre-Funded Warrants (see Note 13), shares				1,658,000
Issuance of common stock upon exercise of Pre-Funded Warrants (see Note 13), amount	0	$ 0	$ 0	$ 0	0	0
Balance, shares at Sep. 30, 2024		12,656	0	3,452,652
Balance, amount at Sep. 30, 2024	$ 12,826	$ 0	$ 0	$ 0	$ 299,550	$ (286,724)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (11,015)	$ (69,903)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on impairment of goodwill	0	60,934
Depreciation and amortization	1,578	1,558
Stock-based compensation	36	1,222
Change in fair value of royalties payable	2,823	(5,333)
Changes in operating assets and liabilities:
Accounts receivable	30	25
Inventories	(7)	(12)
Prepaid expenses and other assets	108	913
Operating lease right-of-use assets and lease liabilities	(1)	5
Current portion of royalties payable	17	0
Accounts payable	244	(849)
Accrued expenses	(236)	(7,092)
Interest payable to related parties	16	(198)
Net cash used in operating activities	(6,407)	(18,730)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(67)	(58)
Cash acquired as part of business combination	0	15
Net cash used in investing activities	(67)	(43)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants	0	238
Proceeds from issuance of common stock and other equity-classified contracts from the September 2024 Public Offering, net of issuance costs	2,612	0
Proceeds from notes payable due to related parties	1,500	0
Payment on note payable	(184)
Proceeds from note payable	249	0
Proceeds from exercise of warrants	0	1,326
Payments of costs related to the warrant repricing	0	(181)
Payments of convertible promissory notes and accrued interest	0	(250)
Proceeds from the private placement of securities	0	8,000
Payments of offering costs related to the private placement of securities	0	(640)
Net cash provided by financing activities	4,177	8,493
NET CHANGE IN CASH AND CASH EQUIVALENTS	(2,297)	(10,280)
CASH AND CASH EQUIVALENTS, beginning of period	3,565	15,859
CASH AND CASH EQUIVALENTS, end of period	1,268	5,579
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash payments for interest	25	198
SUPPLEMENTAL DISCLOSURE OF NONCASH FINANCING AND INVESTING ACTIVITIES
Non-cash consideration for Catheter acquisition	0	72,544
Property and equipment reclassified from inventories	19	0
Conversion of Series A Convertible Preferred Stock for common stock	$ 0	$ 1

Organization and Nature of Oper

Organization and Nature of Operations	9 Months Ended
	Sep. 30, 2024
Organization and Nature of Operations
Organization and Nature of Operations	Note 1. Organization and Nature of Operations The Company Catheter Precision, Inc. ("Catheter" or the "Company”) was incorporated in California on September 4, 2002, and reincorporated in Delaware in July 2018. Catheter was initially formed to develop, commercialize and market its advanced excimer laser-based platform for use in the treatment of vascular and dermatological immune-mediated inflammatory diseases. On January 9, 2023, Catheter entered into the Amended and Restated Agreement and Plan of Merger (the "Merger Agreement") with Catheter Precision, Inc. (“Old Catheter”), a privately held Delaware corporation. Under the terms of the Merger Agreement, Old Catheter became a wholly owned subsidiary of Catheter, together referred to as the Company, in a stock-for-stock merger transaction (the "Merger"). Prior to the Merger, Catheter developed an advanced excimer laser-based platform for use in the treatment of vascular immune-mediated inflammatory diseases designed to be used as a tool in the treatment of Peripheral Artery Disease, which commonly occurs in the legs. After the Merger, and looking forward, this legacy Destruction of Arteriosclerotic Blockages by laser Radiation Ablation laser and single-use catheter (together referred to as "DABRA") and related assets were no longer used. The Company ceased operations and marketing with respect to DABRA, and Catheter’s legacy lines of business were discontinued. Instead, the Company shifted the focus of its operations to Old Catheter’s product lines. Accordingly, the Company’s current activities primarily relate to Old Catheter’s historical business, which comprises the design, manufacture and sale of new and innovative medical technologies focused in the field of cardiac electrophysiology (“EP”). One of the Company’s two primary products is the VIVO System, which is an acronym for View into Ventricular Onset (“VIVO” or “VIVO System”). VIVO is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO System is commercially available in the European Union and has been placed at several hospitals in Europe. United States Food and Drug Administration ("FDA") 510(k) clearance was received, and the Company began a limited commercial release of VIVO in 2021 in the United States. The Company’s newest product, LockeT ® The Company’s product portfolio also includes the Amigo ® Reverse Stock Split On July 3, 2024, at the annual meeting of stockholders of the Company, the stockholders approved an amendment to the Amended and Restated Certificate of Incorporation of the Company (the “Amendment”), which included a decrease in the authorized common stock and authorization for the Board, in its discretion, to effect a reverse stock split within specified parameters. The Amendment was effective July 15, 2024, reducing the authorized common stock to 30 million shares and effecting a reverse stock split in which each ten (10) shares of the Company’s common stock, par value $0.0001 per share, issued and outstanding immediately prior to the effective time, automatically combined into one (1) validly issued, fully paid and non-assessable share of the Company’s common stock, par value $0.0001 per share. No fractional shares were issued as a result of the Reverse Stock Split. Stockholders who would otherwise have been entitled to receive a fractional share were entitled to receive their pro rata portion of the net proceeds obtained from the aggregation and sale by the exchange agent of the fractional shares resulting from the reverse stock split (reduced by any customary brokerage fees, commissions and other expenses). All references to share and per share amounts for all periods presented in the unaudited condensed consolidated financial statements have been retrospectively restated to reflect this Reverse Stock Split. All rights to receive shares of common stock under outstanding securities, including but not limited to, warrants and options were adjusted to give effect to the reverse stock split. Furthermore, proportionate adjustments were made to the per share exercise price and the number of shares of Common Stock that may be purchased upon exercise of outstanding warrants and stock options granted by the Company, and the number of shares of Common Stock reserved for future issuance under the Company’s Equity Incentive Plan. Going Concern The unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from the outcome of this uncertainty. The Company has incurred recurring net losses from operations and negative cash flows from operating activities since inception. As of September 30, 2024, the Company had cash and cash equivalents of approximately $1.3 million. For the nine months ended September 30, 2024, the Company used $6.4 million in cash for operating activities. As of September 30, 2024, the Company had an accumulated deficit of approximately $287 million. Management expects operating losses and negative cash flows to continue for the foreseeable future as the Company invests in its commercial capabilities. These negative cash flows and additional costs associated with the Merger paid during the year ended December 31, 2023, have substantially depleted the Company’s cash. Following the Merger with Old Catheter, Management further reduced costs while assuming the operating costs of Old Catheter. Management will continue to monitor its operating costs and seek to reduce its current liabilities. Such actions may impair its ability to proceed with certain strategic activities. From May to July 2024, the Company issued five short-term promissory notes with related parties totaling $1.5 million with an 8% interest rate and a maturity date of August 30, 2024 (the “Related Party Notes”). On August 23, 2024, the Company amended the Related Party Notes to extend the maturity date to January 31, 2026. As part of the amendment, all interest accrued as of the amendment date was repaid to the noteholders and the contractual interest rate increased to 12% per annum as of the amendment date. See Note 9, Notes Payable for additional information. On August 30, 2024, the Company entered into an Underwriting Agreement (the “Underwriting Agreement”) with Ladenburg Thalmann & Co. Inc. as representative (the “Representative”) of the underwriters named in the Underwriter Agreement (the “Underwriters”). Pursuant to the Underwriting Agreement, the Company completed a public offering of its securities on September 3, 2024 (the “September 2024 Public Offering”) and sold an aggregate of (i) 805,900 Common Stock Units and (ii) 2,773,000 Pre-Funded Units. The Company collected gross proceeds of approximately $3.6 million before deducting underwriting discounts, commissions, and offering expenses payable by the Company of $1.0 million. See Note 13, Equity Offerings for additional information. On October 24, 2024, the Company entered into Warrant Inducement Offer Letters (the “2024 Inducement Offer”) with certain holders of the Company’s existing warrants. Following the closing of the 2024 Inducement Offer, such warrant holders immediately exercised up to an aggregate of (i) 33,160.8 Series E Warrants, (ii) 499,909.34 Series F Warrants, (iii) 499,909.34 Series G Warrants, (iv) 1,990,000 Series H Warrants, and (v) 2,325,000 Series I Warrants (collectively the “Existing Warrants”) to purchase up to approximately 5.3 million shares of the Company’s Common Stock at a reduced exercise price of $0.70 per share. In consideration for the immediate exercise of the Existing Warrants for cash, the Company agreed to issue unregistered new Series K Common Stock Purchase Warrants (“Series K Warrants”) to purchase up to 10.7 million shares of common stock. The Company expects to receive aggregate gross proceeds of approximately $3.7 million in cash from the exercise of these warrants pursuant to the 2024 Inducement Offer, prior to deducting placement agent fees and offering expense of $0.4 million. As of the date of the 2024 Inducement Offer, 578,900 Series H and 1,078,900 Series I warrants remained unexercised. As additional consideration, the Company issued placement agent warrants to purchase up to 320,879 shares of common stock on the same terms as the Series K warrants, except the exercise price is $1.085 per share and have a termination date of October 28, 2029. Management estimates that based on the Company’s liquidity resources, there is substantial doubt about the Company’s ability to continue as a going concern within 12 months from the date of issuance of the unaudited condensed consolidated financial statements. The accompanying unaudited condensed consolidated financial statements have been prepared on the basis of the Company continuing to operate in the normal course of business and do not reflect any adjustments to the assets and liabilities related to the substantial doubt of its ability to continue as a going concern. Management’s ability to continue as a going concern is dependent upon its ability to raise additional funding. Management plans to raise additional capital through public or private equity or debt financings to fulfill its operating and capital requirements for at least 12 months from the date of the issuance of the unaudited condensed consolidated financial statements. However, the Company may not be able to secure such financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity securities to raise additional funds, its existing stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the Company’s existing stockholders.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2024
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies Principles of Consolidation The unaudited condensed consolidated financial statements of the Company include the accounts of the Company and Old Catheter. All intercompany transactions have been eliminated in consolidation. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP"). The Financial Accounting Standards Board (“FASB”) establishes these principles to ensure financial condition, results of operations, and cash flows are consistently reported. Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative nongovernmental GAAP as found in the FASB Accounting Standards Codification ("ASC"). Certain footnotes and other financial information normally required by U.S. GAAP have been condensed or omitted in accordance with instructions to Form 10-Q and Article 8 of Regulation S-X. In the opinion of management, such statements include all adjustments which are considered necessary for fair presentation of the unaudited condensed consolidated financial statements of the Company. The operating results presented herein are not necessarily an indication of the results that may be expected for the year. The unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited Consolidated Financial Statements included in its Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (“SEC”) on April 1, 2024. Use of Estimates The preparation of the unaudited condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results may differ materially from those estimates. The Company’s unaudited condensed consolidated financial statements are based upon a number of estimates including, but not limited to, the accounting for the Old Catheter business combination (see Note 3, Business Combination), allowance for credit losses, evaluation of impairment of long-lived assets and goodwill, valuation of long-lived assets and their associated estimated useful lives, reserves for warranty costs, fair value of royalties payable, evaluation of probable loss contingencies, fair value of preferred stock and warrants issued, and the fair value of equity awards granted. Concentrations of Credit Risk The Company's financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Cash equivalents represent short-term, highly liquid investments with maturities of 90 days or less at the date of purchase. The Company generally maintains balances in various operating accounts at financial institutions that management believes to be of high credit quality, in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its cash and cash equivalents and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other hedging arrangements. The Company extends credit to customers in the normal course of business. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the condensed consolidated financial statements. The Company does not require collateral from its customers to secure accounts receivable. The Company had three and five customers that represented 90% and 86% of the Company's consolidated revenue for the three and nine months ended September 30, 2024, respectively; and three and four customers that represented 71% and 73% of the Company's consolidated revenue for the three and nine months ended September 30, 2023, respectively. Reclassifications Certain prior year financial statement amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on our previously reported results of operations or accumulated deficit. Segment Reporting The Company’s Board of Directors and executive management team represents the entity’s chief operating decision makers. To date, the Company’s executive management team has viewed the Company’s operations as one segment that includes the marketing, sales, and development of medical technologies in the field of cardiac electrophysiology. As a result, the financial information disclosed materially represents all of the financial information related to the Company’s sole operating segment. Cash and Cash Equivalents Cash equivalents primarily represent funds invested in readily available checking and money market accounts. The Company maintains deposits in financial institutions in excess of federally insured limits of $250,000, in the amount of $987 thousand at September 30, 2024. Fair Value Measurements Fair value represents the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants and is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. A three-tier fair value hierarchy is used to identify inputs used in measuring fair value as follows: Level 1 - Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets; Level 2 - Inputs other than the quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and Level 3 - Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions. Cash equivalents, prepaid expenses, trade accounts receivable, accounts payable, and accrued expenses are reported on the condensed consolidated balance sheets at carrying value which approximates fair value due to the short-term maturities of these instruments. The following table details the fair value measurements within the fair value hierarchy of the Company’s financial instruments: Fair value at September 30, 2024 Total Level 1 Level 2 Level 3 Assets: Cash Equivalents Mutual Funds $ 1,237 $ 1,237 $ — $ — Money Market Funds 18 18 — — Total assets $ 1,255 $ 1,255 $ — $ — Liabilities Royalties payable $ 9,797 $ — $ — $ 9,797 Total liabilities $ 9,797 $ — $ — $ 9,797 Fair value at December 31, 2023 Total Level 1 Level 2 Level 3 Assets: Cash Equivalents Mutual Funds $ 3,397 $ 3,397 $ — $ — Money Market Funds 10 10 — — Total assets $ 3,407 $ 3,407 $ — $ — Liabilities Royalties payable $ 6,974 $ — $ — $ 6,974 Total liabilities $ 6,974 $ — $ — $ 6,974 The royalties payable have significant unobservable inputs that are not supported by any market data. As such, the Company developed its own assumptions and identified the inputs as Level 3. The revenue adjusted discount rate (“RADR”) was calculated using a weighted average cost of capital (“WACC”) approach for the measurement of the Level 3 liability. The RADR considers the WACC from the Company’s impairment analysis and adjusts certain inputs to represent the risk profile of the revenue. Under the cost of equity section, the risk-free rate has changed to be commensurate with the royalties payable term. Additionally, the Beta and Company Specific Risk Premium have been adjusted to Revenue Beta and Revenue Specific Risk Premium, respectively. This adjustment was calculated by multiplying the respective metric by the quotient of equity volatility over revenue volatility. The remaining inputs from the Impairment WACC have remained unchanged. The following table summarizes the significant unobservable inputs used in the fair value measurement of Level 3 instruments as of September 30, 2024 and December 31, 2023: September 30, 2024 Instrument Valuation Technique Unobservable Input Input Range Royalties Payable Discounted future cash flows Revenue adjusted discount rate 20% December 31, 2023 Instrument Valuation Technique Unobservable Input Input Range Royalties Payable Discounted future cash flows Revenue adjusted discount rate 28% Increases or decreases in the fair value of the royalties payable can result from updates to assumptions, such as changes in discount rates, project cash flows, among other assumptions. Judgment is used in determining these assumptions as of the initial valuation date and at each subsequent reporting period. Changes or updates to assumptions could have a material impact on the reported fair value, the change in fair value, and the results of operations in any given period. Accounts Receivable and Allowances for Credit Losses Under the Current Expected Credit Loss ("CECL") impairment model, the Company develops and documents its allowance for credit losses on its trade receivables based on three portfolio segments: Hospitals - United States, Hospitals - Europe, and Distributors. The determination of portfolio segments is based primarily on the customers’ industry and geographical location. Trade accounts receivable are recorded at invoiced amounts, net of allowance for credit losses, if applicable, and are unsecured and do not bear interest. The allowance for credit losses is based on the probability of future collection under the CECL impairment model in which the Company determines its estimated loss rates based on an aging schedule. The Company also considers reasonable and supportable current information in determining its estimated loss rates, such as external forecasts, macroeconomic trends or other factors, including customers’ credit risk and historical loss experience. The adequacy of the allowance is evaluated on a regular basis. Trade account balances are written off after all means of collection are exhausted and the balance is deemed uncollectible. Subsequent recoveries are credited to the allowance for credit losses, if any. Changes in the allowance are recorded as adjustments to bad debt expense in the period incurred. The allowance for credit losses within trade accounts receivable was not material as of September 30, 2024 and December 31, 2023. Inventories Inventories are stated at the lower of cost (determined by the first-in, first-out method) or net realizable value. Cost includes materials, labor, and manufacturing overhead related to the purchase and production of inventories. The Company reduces the carrying value of inventories for those items that are potentially in excess, obsolete or slow-moving based on changes in customer demand, technological developments or other economic factors. Property and Equipment Property and equipment are recorded at cost and depreciated on a straight-line basis over their estimated useful lives as follows: Machinery and equipment 2-5 years Computer hardware and software 1-5 years LockeT animation video 3 years VIVO DEMO/Clinical Systems 1-5 years Leasehold improvements are depreciated over the shorter of the useful life of the leasehold improvement or the term of the underlying property’s lease. The Company periodically reviews the residual values and estimated useful lives of each class of its property and equipment for ongoing reasonableness, considering long-term views on its intended use of each class of property and equipment and the planned level of improvements to maintain and enhance assets within those classes. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the account balances and any resulting gain or loss is recognized in income for the period. The cost of repairs and maintenance is expensed as incurred, whereas significant betterments are capitalized. Impairment of Long-Lived Assets In accordance with ASC 360, Impairment and Disposals of Long-lived Assets The Company concluded there was no impairment as of September 30, 2024. Goodwill In accordance with ASC 350, Intangibles – Goodwill and Other To determine whether goodwill is impaired, annually or more frequently if needed, the Company performs a multi-step impairment test. The Company first has the option to assess qualitative factors to determine if it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value. The Company may also elect to skip the qualitative testing and proceed directly to the quantitative testing. When performing quantitative testing, the Company first estimates the fair values of its reporting units using a combination of an income and market approach. To determine fair values, the Company is required to make assumptions about a wide variety of internal and external factors. Significant assumptions used in the impairment analysis include financial projections of free cash flow (including significant assumptions about operations, including the rate of future revenue growth, capital requirements, and income taxes), long-term growth rates for determining terminal value and discount rates. Comparative market multiples are used to corroborate the results of the discounted cash flow test. These assumptions require significant judgment. Pursuant to ASU 2017-04, Simplifying the Test for Goodwill Impairment Royalties Payable The Company is obligated to pay royalties under various royalty agreements executed by Old Catheter. On January 9, 2023, prior to the consummation of the Merger, Old Catheter entered in an agreement with its Convertible Promissory Noteholders (“Noteholders”), which substantially consisted of amounts due to David A. Jenkins, previously Old Catheter's Chairman of the Board of Directors, and, currently, the Company’s Executive Chairman of the Board of Directors and Chief Executive Officer, to forgive all accrued interest and future interest expense in exchange for a future royalty right. The Company will pay to the Noteholders a royalty equal to 11.82% of net sales of LockeT, commencing on the first commercial sale through December 31, 2035 (see Note 10, Royalties Payable). The Company recognizes a current liability for royalty fees incurred and payable to the Noteholders based on actual sales of LockeT devices. The liability is recorded as current portion of royalties payable in the condensed consolidated balance sheet. The Company further recognizes a liability for future, estimated royalty payments to the Noteholders at fair value, which is recorded as royalties payable in the condensed consolidated balance sheet (the “Royalties Payable”). The fair value of the Royalties Payable is an estimate that is based on the projected sales of LockeT through the end of 2035. The projected sales are then multiplied by the royalty rate of 11.82% and discounted back to their present value using the RADR. At each reporting date, the fair value of the Royalty Payable is re-measured in connection with any changes to Management’s projections as a change in estimate. Product Warranty The Company offers product warranties against defects in material and workmanship when properly the products are used for their intended purpose and properly maintained. Warranty expenses are included in cost of revenues in the accompanying unaudited condensed consolidated statements of operations. Changes in estimates to previously established warranty accruals result from current period updates to assumptions regarding repair and product recall costs and are included in current period warranty expense. As of September 30, 2024 and December 31, 2023, there was no accrued warranty balance. Distinguishing Liabilities from Equity The Company evaluates equity or liability classification for freestanding financial instruments, including convertible preferred stock, warrants, and options, pursuant to the guidance under ASC Topic 480 , Distinguishing Liabilities from Equity If a freestanding financial instrument does not represent an outstanding equity share and does not meet liability classification under ASC 480, the Company then assesses whether the freestanding financial instrument is indexed to its own stock and meets equity classification pursuant to ASC 815-40, Derivatives and Hedging Revenue Recognition In accordance with ASC Topic 606, Revenue from Contracts with Customers Pursuant to ASC 606, the Company applies the following five steps to each customer contract: Step 1: Identify the contract with the customer Step 2: Identify the performance obligations in the contract Step 3: Determine the transaction price in the contract Step 4: Allocate the transaction price to the performance obligations in the contract Step 5: Recognize revenue when the Company satisfies a performance obligation VIVO System The VIVO System offers 3D cardiac mapping to help localize the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to electrophysiology studies. Customers are provided with VIVO Positioning Patch Sets, which are custom patches, that are used in conjunction with the VIVO System. The VIVO Positioning Patch Sets are integral to the functionality of the VIVO System. The VIVO System, including the VIVO Positioning Patch Sets, represents the Company’s primary performance obligation. The Company recognizes revenue when physical possession and control of the VIVO System is transferred to the customer upon delivery. The Company also offers customers software upgrades for the VIVO System, which may be purchased and paid in advance at contract inception. Software upgrades represent stand-ready services, whereby the Company promises to provide software upgrades to the customer when and as upgrades are available. Software upgrade services may be offered for initial contract terms of one to multiple years. Customers have the option to renew terms for software upgrades services at the end of each term. The software upgrade services represent the Company's second performance obligation, which is recognized evenly over time over the contract term. The Company invoices the customer after physical possession and control of the VIVO System is transferred to the customer and recognizes revenue upon delivery. The timing of payment for the corresponding invoices is dependent upon the credit terms identified in each contract. The Company invoices customers who pay for software upgrades in advance in conjunction with the invoice for the delivery of the VIVO System, and subsequent renewals of software upgrades are invoiced at the inception of the term. Revenue for these stand-ready services is recognized evenly over the term of the upgrade period, consistently with similar stand-ready services under ASC 606. Similar to the delivery of the VIVO System, the timing of payment for the corresponding invoices is dependent upon the credit terms identified in each contract. Revenue is recognized at the point in time that the product is delivered to the customer. LockeT LockeT was launched by the Company in February 2023 and is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure. LockeT is intended to temporarily secure sutures and aid clinicians in locating and removing sutures efficiently. The LockeT device represents a performance obligation in the customer contract. The Company recognizes revenue when it transfers control of the LockeT device to the customer, which happens when the Company delivers the product to the customer. For both LockeT and VIVO System, the Company has elected the practical expedient to expense costs incurred to obtain a contract, rather than recognizing these costs as an asset at the time of occurrence. Disaggregation of Revenue The following table summarizes disaggregated product sales by geographic area (in thousands): For the Three Months Ended September 30, For the Nine Months Ended September 30, 2024 2023 2024 2023 Product Sales US $ 62 $ 110 $ 129 $ 241 Europe 34 23 142 73 $ 96 $ 133 $ 271 $ 314 Shipping and Handling Costs Shipping and handling costs charged to customers are included in net product sales, while all other shipping and handling costs are included in selling, general and administrative expenses in the accompanying unaudited condensed consolidated statements of operations. Advertising and Marketing Advertising costs are expensed as incurred and included in selling, general and administrative expenses. Advertising costs were $31 thousand and $127 thousand during the three and nine months ended September 30, 2024, respectively. Advertising costs were $309 thousand and $914 thousand during the three and nine months ended September 30, 2023, respectively. Patents The Company expenses patent costs, including related legal costs, as incurred and records such costs as selling, general and administrative expenses in the accompanying unaudited condensed consolidated statements of operations. Research and Development Major components of research and development costs include consulting, research grants, supplies and clinical trial expenses. Research and development expenses are charged to operations in the period incurred. Stock-Based Compensation The Company records stock-based compensation expense associated with stock options, restricted stock awards (“RSAs”) and restricted stock units (“RSUs”) issued to employees, members of the Company’s board of directors and consultants in accordance with the guidance under ASC Topic 718 , Compensation – Stock Compensation As a result of the Merger, all unvested Old Catheter stock options were subject to accelerated vesting and became fully vested as of the closing date of the business combination. The Company recognized the fair value of the replacement options as included in consideration transferred to the extent they do not exceed the fair value of the equivalent Old Catheter options. Any incremental fair value was recognized in compensation expense in the post-combination period, with this recognized as a Day 1 expense due to the Old Catheter options becoming fully vested concurrent with the closing of the business combination. Income Taxes The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences reverse. Any resulting net deferred tax assets are evaluated for recoverability and, accordingly, a valuation allowance is provided when it is more likely than not that all or some portion of the deferred tax asset will not be realized. The Company accounts for uncertainty in income taxes using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining whether it is more likely than not that the position will be sustained on an audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. An uncertain tax position is considered effectively settled on completion of an examination by a taxing authority if certain other conditions are satisfied. Should the Company incur interest and penalties relating to tax uncertainties, such amounts would be classified as a component of interest expense and other expense, respectively. Basic and Diluted Net Loss per Share of Common Stock Earnings per share attributable to common stockholders is calculated using the two-class method, which is an earnings allocation formula that determines earnings per share for the holders of the Company’s common shares and participating securities. The Company’s Series A Convertible Preferred Stock, Series X Convertible Preferred Stock, and outstanding warrants contain participating rights in distributions made to common stockholders and, therefore, are participating securities. The Company did not declare nor pay any dividends nor distributions in the current period. Furthermore, the participating securities do not include a contractual obligation to share in the losses of the Company and are not included in the calculation of net loss per share in the periods that have a net loss. In addition, common stock equivalent shares (whether or not participating) are excluded from the computation of diluted earnings per share in periods in which they have an anti-dilutive effect on net loss per common share. Diluted net loss per share is computed using the more dilutive of (a) the two-class method or (b) the if-converted method and treasury stock method, as applicable. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. Diluted net loss per share is equivalent to basic net loss per share for the periods presented herein because common stock equivalent shares from warrants, stock options, non-vested restricted stock awards, restricted stock units, Series A Convertible Preferred Stock, and Series X Convertible Preferred Stock were antidilutive (see Note 12, Net Loss per Share). Net loss attributable to common stockholders consists of net income or loss, as adjusted for actual and deemed dividends declared. The Company recorded a deemed dividend for the modification of existing warrants and issuance of new warrants during the three and nine months ended September 30, 2023 of $0 and $0.8 million, respectively. The deemed dividend is added to the net loss in determining the net loss available to common stockholders for the three and nine months ended September 30, 2023. There was no deemed dividend for the three and nine months ended September 30, 2024. Recently Announced Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures

Business Combination

Business Combination	9 Months Ended
	Sep. 30, 2024
Business Combination
Business Combination	Note 3. Business Combination On January 9, 2023, the Company completed the acquisition of Old Catheter for the purpose of acquiring Old Catheter’s existing and developing product lines based on unique electrophysiology technology. Pursuant to the Merger Agreement, all Old Catheter common stock shares issued and outstanding and convertible promissory notes, representing an aggregate principal of $25.2 million, were converted into a right to receive 14,649.592 shares of a new class of the Company’s preferred stock, designated Series X Convertible Preferred Stock. Additionally, all outstanding stock options to purchase Old Catheter common stock were assumed and converted into options to purchase approximately 75,367 shares of the Company's common stock. The total purchase consideration for the Merger was $72.5 million which represents the sum of the (i) estimated fair value of the 14,649.592 Series X Convertible Preferred Stock issued and (ii) the portion of the estimated fair value of $3.4 million representing the Company stock options issued in replacement of Old Catheter share-based payment awards as required under FASB Topic 805, Business Combinations ("Topic 805") The fair value of the Series X Convertible Preferred Stock includes certain discounts applied to the closing stock price of the Company, on January 9, 2023, of $60.90 per share. The following table summarizes the fair value of the consideration associated with the Merger ($ in thousands): Description Fair Value as of January 9, 2023 Fair value of 14,649.592 Series X convertible preferred stock issued $ 69,140 Fair value of Old Catheter’s fully vested stock options 3,404 Total Purchase Price $ 72,544 The Merger was accounted for as a business combination in accordance with Topic 805, and the Company has been determined to be the accounting acquirer. The Company allocated the purchase price to the assets acquired and liabilities assumed at fair value. The purchase price allocation reflects various fair value estimates and analyses, including certain tangible assets acquired and liabilities assumed, the valuation of intangible assets acquired, liabilities assumed, and goodwill, which were subject to change within the measurement period as valuations were being finalized (generally one year from the acquisition date). Measurement period adjustments were recorded in the reporting period in which the estimates are finalized, and adjustment amounts were determined. During the three months ended June 30, 2023, the Company recorded measurement period adjustments based on changes to certain estimates and assumptions and their related impact to the purchase price allocation. Developed technology was revised from $35.1 million to $27.0 million; trademarks were revised from $1.7 million to $1.3 million; customer relationships were revised from $220 thousand to $62 thousand; goodwill was revised from $56.0 million to $60.9 million; and royalties payable were revised from $7.6 million to $14.2 million. The following table summarizes the final purchase price allocations relating to the Merger (in thousands): Description Fair Value Assets acquired: Cash and cash equivalents $ 15 Accounts receivable 71 Inventories 52 Prepaid expenses and other current assets 23 Property and equipment, net 26 Lease right-of-use assets 119 Other assets 8 Developed technology 27,014 Customer relationships 62 Trademarks 1,285 Goodwill 60,934 Total assets acquired $ 89,609 Liabilities assumed: Accounts payable $ 922 Accrued expenses 1,389 Lease liability 124 Interest payable 198 Convertible promissory notes 250 Royalties payable 14,182 Total liabilities assumed 17,065 Total purchase price $ 72,544 All intangible assets acquired are subject to amortization and their associated acquisition date fair values and useful lives are as follows: Intangible Assets Fair Value Useful Life Developed technology- VIVO $ 8,244 15 Developed technology- LockeT 18,770 14 Customer relationships 62 6 Trademark- VIVO 876 9 Trademark- LockeT 409 9 $ 28,361 Notwithstanding the above, as described in Note 7, management determined that there were indicators of asset impairment during the nine months ended September 30, 2023, and assessed the carrying values of the Company’s intangible assets and goodwill. As a result of the impairment analysis in prior periods, the Company recorded an impairment charge of $60.9 million for the nine months ended September 30, 2023. This amount represented the purchase price amount ascribed to goodwill. Transaction costs incurred in connection with this business combination amounted to approximately $0 and $1.7 million during the three and nine months ended September 30, 2023, respectively. Pro Forma Financial Information The following table represents the revenue, net loss and net loss per share effect of the acquired company, as reported on a pro forma basis as if the acquisition occurred on January 1, 2023. These pro forma results are not necessarily indicative of the results that would have occurred if the acquisition had occurred on the first day of the period presented, nor does the pro forma financial information purport to represent the results of operations for future periods. The following information for the three and nine months ended September 30, 2023 is presented in thousands except for the per share data (in thousands, except per share data): Three Months Ended September 30, Nine Months Ended September 30, 2023 2023 Revenues $ 133 $ 317 Net loss $ (1,927 ) $ (70,073 ) Net loss attributable to common stockholders $ (1,927 ) $ (70,873 ) Basic and diluted net loss per share – on a pro forma basis $ (0.28 ) $ (14.07 )

Inventories

Inventories	9 Months Ended
	Sep. 30, 2024
Inventories
Inventories	Note 4. Inventories Inventories consisted of the following (in thousands): September 30, 2024 December 31, 2023 Raw materials $ 4 $ 27 Finished goods 28 17 Inventories $ 32 $ 44 There were no charges for inventory obsolescence or allowance recorded during the three and nine months ended September 30, 2024 and 2023.

Property and Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2024
Property and Equipment
Property and Equipment	Note 5. Property and Equipment, net Property and equipment, net consisted of the following (in thousands): September 30, 2024 December 31, 2023 Machinery and equipment $ 29 $ 16 Computer hardware and software 29 17 LockeT Animation Video 29 — VIVO DEMO/Clinical Systems 101 69 Property and equipment, gross 188 102 Accumulated depreciation (77 ) (32 ) Property and equipment, net $ 111 $ 70 Depreciation expense was $19 thousand and $45 thousand for the three and nine months ended September 30, 2024, respectively. Depreciation expense was $9 thousand and $26 thousand for the three and nine months ended September 30, 2023, respectively.

Intangible Assets

Intangible Assets	9 Months Ended
	Sep. 30, 2024
Intangible Assets
Intangible Assets	Note 6. Intangible Assets The following table summarizes the Company’s intangible assets as of September 30, 2024 (in thousands): Estimated Useful Life in Years Gross Carrying Amount at January 9, 2024 Accumulated Amortization Net Book Value at September 30, 2024 Developed technology ‐ VIVO 15 $ 8,244 $ (962 ) $ 7,282 Developed technology ‐ LockeT 14 18,770 (2,347 ) 16,423 Customer relationships 6 62 (18 ) 44 Trademarks/trade names ‐ VIVO 9 876 (170 ) 706 Trademarks/trade names ‐ LockeT 9 409 (79 ) 330 $ 28,361 $ (3,576 ) $ 24,785 The following table summarizes the Company’s intangible assets as of December 31, 2023 (in thousands): Estimated Useful Life in Years Gross Carrying Amount at January 9, 2023 Accumulated Amortization Net Book Value at December 31, 2023 Developed technology ‐ VIVO 15 $ 8,244 $ (550 ) $ 7,694 Developed technology ‐ LockeT 14 18,770 (1,341 ) 17,429 Customer relationships 6 62 (10 ) 52 Trademarks/trade names ‐ VIVO 9 876 (97 ) 779 Trademarks/trade names ‐ LockeT 9 409 (45 ) 364 $ 28,361 $ (2,043 ) $ 26,318 The estimated future amortization expense for the next five years and thereafter is as follows (in thousands): Years ending December 31, Future Amortization Expense Remainder of 2024 $ 510 2025 2,043 2026 2,043 2027 2,043 2028 2,043 Thereafter 16,103 Total $ 24,785 The Company uses the straight-line method to determine the amortization expense for its definite lived intangible assets. Amortization expense, included within selling, general and administrative expenses, relating to the Company's intangible assets was $0.5 million and $1.5 million for the three and nine months ended September 30, 2024 and 2023, respectively. The weighted average remaining amortization period for the Company’s intangible assets as of September 30, 2024, is 12.32 years.

Goodwill

Goodwill	9 Months Ended
	Sep. 30, 2024
Goodwill
Goodwill	Note 7. Goodwill In connection with the Merger, the excess of the purchase price over the estimated fair value of the net assets assumed of $60.9 million was recognized as goodwill. The Merger was accounted for as a business combination in accordance with Topic 805, and the Company has been determined to be the accounting acquirer. The Company allocated the purchase price to the assets acquired and liabilities assumed at fair value. During the three months ended June 30, 2023, the Company recorded measurement period adjustments based on changes to certain estimates and assumptions and their related impact to the purchase price allocation. As a result, goodwill was revised from $56.0 million to $60.9 million. The Company tests Goodwill for impairment at the reporting unit level annually in the fourth quarter or more frequently if a change in circumstances or the occurrence of events indicates that potential impairment exists. Due to a sustained decrease in the Company’s share price during the quarter ended March 31, 2023, the Company concluded that, in accordance with ASC 350, a triggering event occurred indicating that potential impairment exists and required the Company to assess if impairment exists as of March 31, 2023. In accordance with ASC 350, the Company performed a quantitative goodwill impairment test, which resulted in the carrying amount of the reporting unit exceeding the estimated fair value of the reporting unit, indicating that the goodwill of the reporting unit was impaired. The Company utilized a combination of an income and market approach to assess the fair value of the reporting unit. The income approach considered the discounted cash flow model, considering projected future cash flows (including timing and profitability), discount rate reflecting the risk inherent in future cash flows, perpetual growth rate, and projected future economic and market conditions. The guideline public company market approach considered marketplace earnings multiples from within a peer public company group. As of December 31, 2023, cumulative goodwill impairment charges of $60.9 million were incurred related to the Company’s single reporting unit and no goodwill remains as of this date.

Accrued Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2024
Accrued Expenses
Accrued Expenses	Note 8. Accrued Expenses Accrued expenses consisted of the following (in thousands): September 30, 2024 December 31, 2023 Legal expenses $ 60 $ 102 Offering costs 1,356 1,356 Compensation and related benefits 33 43 Other accrued expenses 48 232 Accrued expenses $ 1,497 $ 1,733 The product warranty accrual related to the voluntary recall of DABRA catheters was initiated in September 2019. The recall was closed by the FDA in July 2023 and no claims have been submitted in approximately 2 years. As such, the Company derecognized the warranty liability of $192 thousand as of December 31, 2023. As of September 30, 2024 and December 31, 2023, the accrued warranty balance was $0.

Notes Payable

Notes Payable	9 Months Ended
	Sep. 30, 2024
Notes Payable
Notes Payable	Note 9. Notes Payable Note Payable - Director & Officer Liability Insurance The Company purchased director and officer liability insurance coverage on October 16, 2023 for $447 thousand. A down payment of $157 thousand was made and the remaining balance of $291 thousand was financed over 8 months through a short-term financing arrangement with its insurance carrier. The interest rate on the loan is 8.990%. Interest expense on this loan was $1 thousand and $4 thousand for the three and nine months ended September 30, 2024, respectively. The loan balance was $184 thousand as of December 31, 2023. The loan balance was paid off in May of 2024 and therefore there is no balance as of September 30, 2024. The Company purchased director and officer liability insurance coverage on September 26, 2024 for $293 thousand. A down payment of $44 thousand was made and the remaining balance of $249 thousand was financed over 10 months through a short-term financing arrangement with its insurance carrier. The interest rate on the loan is 9.990%. Interest expense on this loan was $0 for the three and nine months ending September 30, 2024. The loan balance was $249 thousand as of September 30, 2024. Short Term Promissory Notes (collectively, the “Related Party Notes”) On May 30, 2024, David A. Jenkins loaned $500,000 to the Company in exchange for a short-term promissory note. On June 25, 2024, an entity controlled by Mr. Jenkins loaned $150,000 to the Company in exchange for a short-term promissory note. On July 1, 2024 and July 18, 2024, the Company entered into two short-term promissory notes with an affiliate of Mr. Jenkins, where the affiliate loaned $250,000 and $100,000, respectively, to the Company in exchange for the notes. On July 25, 2024, the Company entered into a short-term promissory note with a Trust, of which Mr. Jenkins’ adult daughter is the trustee, where the Trust loaned $500,000 to the Company in exchange for the note. All of these short-term promissory notes (the “Related Party Notes”) had a maturity date of August 30, 2024, and bear interest at the rate of 8% per annum. On August 23, 2024, the Company entered in the first amendment of the Related Party Notes, which extended the maturity date to January 31, 2026 and increased the interest rate to 12% per annum after August 31, 2024. All other terms and conditions remained substantially unchanged. As part of the amendment, the Company paid down all accrued interest to date of $21 thousand. The first amendment was accounted for as a debt modification in accordance with ASC 470-50, Debt Modifications and Extinguishment The Related Party Notes and the debt evidenced thereby, including all principal and interest, accelerate and become immediately due and payable upon the occurrence of certain customary events of default, including failure to pay amounts owing when due, material breach of representations or warranties by the Company (unless waived by the holder of the Related Party Note or cured within 10 days following notice) and/or certain events involving a discontinuation of the Company’s business or certain types of proceedings involving insolvency, bankruptcy, receivership and the like. Interest expense on the Related Party Notes was $33 thousand and $36 thousand for the three and nine months ended September 30, 2024, respectively. The balance of the Related Party Notes and accrued interest was $1.5 million as of September 30, 2024, $16 thousand of which relates to accrued interest and is recorded under interest payable to related parties on the condensed consolidated balance sheets. See Note 19, Related Parties for additional details.

Royalties Payable

Royalties Payable	9 Months Ended
	Sep. 30, 2024
Royalties Payable
Royalties Payable	Note 10 . Royalties Payable LockeT Royalty On January 9, 2023, Old Catheter entered into an agreement with the Noteholders to forgive all accrued interest and future interest expense in exchange for a future royalty right. Under these agreements, the Company is obligated to pay the Noteholders a total royalty equal to approximately 12% of net sales of its LockeT device on a quarterly basis, commencing upon the first commercial sale through December 31, 2035. An additional royalty will be paid to the inventor of the LockeT device as detailed in the Royalty Agreement. In exchange for the assignment and all rights to LockeT, the Company will pay a 5% royalty on net sales up to $1.0 million in royalties, payable annually in arrears, starting with the year ending December 31, 2022. After $1.0 million has been paid, and if, and only if, a US patent is granted by the United States Patent and Trademark Office, the Company will continue to pay a royalty at a rate of 2% of net sales, until total cumulative royalties of $10.0 million have been paid. The royalty payments will apply to revenues through December 31, 2033, then will terminate regardless of whether the full $10.0 million has been paid. The LockeT device had sales during the three and nine months ended September 30, 2024, and as such the Company owes the first royalty payment in relation to the Royalty Agreement. As of September 30, 2024, the Company owes $17 thousand in relation to LockeT sales. AMIGO System Royalty During 2006 and 2007, Old Catheter entered into two investment grant agreements with a non-profit foundation for the purpose of funding the initial development of Old Catheter's AMIGO System, receiving a total of $1.6 million from the foundation. The agreement calls for the payment of the following sales-based royalties, by Old Catheter, to the foundation, upon successful commercialization of the AMIGO System: Royalty Percentage Until Royalty Payment Reaches a Total of 4% $ 1,589,500 2% $ 3,179,000 1% In perpetuity The Company is not actively marketing and selling the AMIGO System. There was no royalty expense recorded for the three and nine months ended September 30, 2024 and 2023 in relation to the AMIGO System. The AMIGO System royalty has been earned and payment has been deferred to a future date. The table below represents the change in fair value of Level 3 royalties payable for the nine months ended September 30, 2024 and 2023 ($ in thousands). See Note 2, Summary of Significant Accounting Policies, for valuation techniques. 2024 2023 Beginning Balance, January 1, $ 6,974 $ — AMIGO royalty payable recognized in connection with the Merger — 159 LockeT royalty payable recognized in connection with the Merger — 14,022 Payments owed on royalties payable 17 — Change in fair value of royalties payable 2,823 (5,333 ) Ending Balance, September 30, $ 9,814 $ 8,848

Leases

Leases	9 Months Ended
	Sep. 30, 2024
Leases
Leases	Note 11. Leases For the three and nine months ended September 30, 2024 and 2023 operating lease expense and cash paid for leases were as follows: For the Three Months Ended September 30, For the Nine Months Ended September 30, 2024 2023 2024 2023 Operating lease expense $ 28 $ 23 $ 80 $ 52 Cash paid for leases $ 25 $ 32 $ 78 $ 62 The Company's lease agreements generally do not provide an implicit borrowing rate. Therefore, the Company used a benchmark approach to derive an appropriate imputed discount rate. The Company benchmarked itself against other companies with similar credit ratings and of comparable quality and derived an imputed rate, which was used in a portfolio approach to discount its real estate lease liabilities. Management used an estimated incremental borrowing rate as detailed below for each lease. Lease Terms and Discount Rate The table below presents certain information related to the weighted average remaining lease term and the weighted average discount rate for the Company’s operating leases, as of September 30, 2024: Weighted average remaining lease term (in years) - operating leases 1.37 Weighted average discount rate - operating leases 8.65 % South Carolina Office Lease Agreement On September 27, 2022, Old Catheter entered into a lease agreement for office space located in Fort Mill, South Carolina. The space is used for office and general use. The term of the lease began on October 1, 2022, is 38 months, and includes two months of free rent from the commencement date of the lease. The lease contains two separate 36 month renewal periods, which require 180 days’ notice of the Company's intention to exercise. As of the date of these condensed consolidated financial statements, the Company does not intend to exercise either of the two extension options. Total rent is $3,435 per month for the first ten months following the two months of free rent, with annual increases on the anniversary of the effective date. The Company has adopted the practical expedient under Topic 842, which permits the Company to account for each separate lease component of a contract and its associated non-lease components as a single lease payment. As a result, beginning at lease inception on October 1, 2022, the Company recognized the lease payments and associated common area maintenance payments as a single lease payment. New Jersey Office Lease Agreement On December 7, 2022, Old Catheter entered into a lease agreement for office space located in Augusta, New Jersey. The space is used for office and general use. The term of the lease is 24 months and began on January 1, 2023. The lease contains one 24 month renewal period, which requires 9 months’ notice if the Company intends to exercise. In March 2024, the Company notified the landlord of its intent to extend the lease for a 12-month period. In April 2024, a lease extension agreement was entered into extending the lease through December 31, 2025. Total rent is $1,207 per month through December 31, 2024, and $1,267 for the remaining term of the extended lease. Park City Office Lease Agreement On March 19, 2023, the Company entered into a lease agreement for office space located in Park City, Utah. The space is used for office and general use. The term of the lease is for 36 months and began on May 1, 2023. The lease contains one 36 month renewal period, which requires 180 days’ notice of the Company's intention to exercise. As of the date of these unaudited condensed consolidated financial statements, the Company does not intend to exercise the extension option. Total rent is $3,200 per month for the first year with an annual increase of three percent per year on the anniversary of the effective date. Future lease payments for all lease obligations for the following five fiscal years and thereafter are as follows (in thousands): Years ending December 31: Operating Lease Remainder of 2024 $ 24 2025 98 2026 14 Total minimum lease payments 136 Less effects of discounting (1 ) Present value of future minimum lease payments $ 135 Operating lease right-of-use assets and lease liabilities for the Company's operating leases were recorded in the condensed consolidated balance sheets as follows: September 30, December 31, 2024 2023 Assets Operating lease right-of-use assets, net $ 127 $ 179 Total lease assets $ 127 $ 179 Liabilities Current liabilities: Current portion of operating lease liabilities $ 99 $ 91 Non-current liabilities: Operating lease liabilities 36 97 Total lease liabilities $ 135 $ 188

Net Loss per Share

Net Loss per Share	9 Months Ended
	Sep. 30, 2024
Net Loss per Share
Net Loss per Share	Note 12. Net Loss per Share The Company’s Series A Convertible Preferred Stock, Series X Convertible Preferred Stock and outstanding warrants to purchase common stock have participation rights to any dividends that may be declared in the future and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income. During periods of loss, no loss is allocated to the participating securities since the holders have no contractual obligation to share in the losses of the Company. Anti-dilutive common share equivalents excluded from the computation of diluted net loss per share at September 30, 2024, consisted of Series X Convertible Preferred Stock of 1,265,601 shares, warrants of 13,170,652, stock options of 95,813, and no Series A convertible preferred stock, restricted stock awards or restricted stock units. Anti-dilutive common share equivalents excluded from the computation of diluted net loss per share at September 30, 2023, consisted of Series A convertible preferred stock of 286,125 shares, Series X convertible preferred stock of 1,267,469 shares, warrants of 1,104,215, stock options of 21,465, and restricted stock units of 2. Net loss attributable to common stockholders for the nine months ended September 30, 2023, consists of net loss, as adjusted for deemed dividends. The Company recorded a deemed dividend for the modification of existing warrants and issuance of the Series E warrants (see Note 13, Equity Offerings) of $0.8 million, during the nine months ended September 30, 2023.

Equity Offerings

Equity Offerings	9 Months Ended
	Sep. 30, 2024
Equity Offerings
Equity Offerings	Note 13. Equity Offerings Warrant Inducement Offer On January 9, 2023, the Company reduced the exercise price of all existing warrants (the "Existing Warrants"), exercisable for 33,161 shares of the Company’s common stock held by an investor (the “Investor”), with exercise prices ranging from $140.00 to $5,265 per share to $40.00 per share (the "2023 Warrant Repricing"). In connection with the 2023 Warrant Repricing, the Company entered into a Warrant Inducement Offer Letter (the "2023 Inducement Letter") with the Investor pursuant to which it would exercise up to all of the 33,161 Existing Warrants (the "Inducement Offer"). In consideration for exercising the Existing Warrants pursuant to the terms of the 2023 Inducement Letter, the Company received approximately $1.3 million in gross proceeds. The Company paid placement agent aggregate cash fees plus other offering costs of approximately $0.2 million related to the Inducement Offer, resulting in net proceeds to the Company of $1.1 million. In consideration for exercising the Existing Warrants pursuant to the terms of the 2023 Inducement Letter, the Company issued the Investor a new Series E common stock purchase warrant (the "Series E Warrant") to purchase 33,161 shares of common stock at an exercise price of $40.00 per share. The Series E Warrant is exercisable for five years from the date of stockholder approval. Exercise of the Series E Warrant in full was subject to approval of the Company's stockholders other than the Investor, which was obtained at a special meeting of the Company's stockholders held on March 21, 2023 (the "Stockholders' Meeting"). The incremental fair value of the repriced warrants amounted to $0.3 million and the fair value of Series E warrant totaled $1.9 million. The relative fair value of such amounts were recorded to additional paid-in capital concurrent with the exercise of the Existing Warrants. As a result of the 2023 Warrant Repricing and Inducement Offer, the Company presents a deemed dividend for the modification of Existing Warrants and issuance of the Series E Warrants of $0 and $0.8 million during the three and nine months ended September 30, 2023, respectively. The deemed dividend was included in net loss attributable to common stockholders in the calculation of net loss per share in the unaudited consolidated condensed statements of operations. The warrants, other than the Series E Warrants that are presented in a separate table below, were valued on the date of the 2023 Warrant Repricing using the Black-Scholes model based on the following assumptions: 5/22/2020 Raise 8/3/2020 Raise Series B Series C Risk-free interest rate 4.06 % 4.06 % 3.60 % 3.66 % Volatility 135.35 % 132.55 % 115.42 % 127.65 % Expected dividend yield 0.00 % 0.00 % 0.00 % 0.00 % Expected life (in years) 2.4 2.6 6.5 4.5 The Series E warrants were also valued on the date of the 2023 Warrant Repricing at approximately $1.9 million using the Black-Scholes model based on the following assumptions: Risk-free interest rate 3.66 % Volatility 124.07 % Expected dividend yield 0.00 % Expected life (in years) 5.0 Private Placement On January 9, 2023, the Company entered into a Securities Purchase Agreement (“Securities Purchase Agreement”) for a private placement (“Private Placement”), with the Investor. Pursuant to the Securities Purchase Agreement, the Investor agreed to purchase, for an aggregate purchase price of approximately $8.0 million, (a) Class A units at a price that was the lower of $3.00 per unit and 90% of the 5 day volume weighted average price of the Company’s common stock immediately prior to obtainment of the approval of the Company’s stockholders of conversion of the PIPE Preferred Stock and PIPE Warrants (as each are defined below), without adjusting such price for the reverse stock split, each consisting of one tenth of one share of common stock, one tenth of one Series F common stock purchase warrant (“Series F Warrant”), and one tenth of one Series G common stock purchase warrant (“Series G Warrant”), and together with the Series F Warrants (the “PIPE Warrants”) and (b) Class B units at a price of $1,000 per unit, each consisting of one share of a new series of the Company’s preferred stock, designated as Series A Convertible Preferred Stock (the “PIPE Preferred Stock”), par value $0.0001, and one tenth of one Series F Warrant and one tenth of one Series G Warrant for each one-tenth of one share of the Company’s common stock underlying the PIPE Preferred Stock (each share of which is convertible into a number of shares of the Company’s common stock equal to $1,000 divided by the lower of $30.00 and 90% of the 5 day volume weighted average closing price, multiplied by ten in order to reflect the impact of the reverse stock split of the Company’s common stock immediately prior to the obtainment of the approval of the Company’s stockholders of conversion of the PIPE Preferred Stock and PIPE Warrants, or the Preferred Conversion Rate). The closing under the Securities Purchase Agreement and the sale and issuance of the Class A units and Class B units (and the issuance of any underlying common stock) were approved at the Stockholders’ Meeting. At the closing of the Private Placement, the Company issued 497,908 Class A units for proceeds of approximately $0.9 million and 7,203 Class B units for proceeds of approximately $7.1 million which contained preferred shares that were convertible into up to 450,123 shares of common stock, as well as the issuance of warrants described below. The PIPE Warrants, including Series F warrants and Series G warrants, are exercisable at an exercise price of $30.00 per share, subject to adjustments as provided under the terms of the PIPE Warrants. The PIPE Warrants are exercisable at any time on or after the closing date of the Private Placement until the expiration thereof, except that the PIPE Warrants cannot be exercised if, after giving effect thereto, the purchaser would beneficially own more than 4.99%, or the Maximum Percentage, of the outstanding shares of common stock of the Company, which Maximum Percentage may be increased or decreased by the purchaser with written notice to the Company to any other percentage specified not in excess of 9.99%. The Series F Warrants have a term of two years from the date of stockholder approval, and the Series G Warrants have a term of six years from the date of stockholder approval. The Series F Warrants and Series G Warrants were approved at the Stockholders’ Meeting. The Series F warrants and Series G warrants were valued, in aggregate, at approximately $5.5 million using the Black-Scholes model based on the following assumptions: Series F Series G Risk-free interest rate 3.8 % 3.4 % Volatility 80.0 % 74.0 % Expected dividend yield 0.0 % 0.0 % Expected life (in years) 2.0 6.0 The proceeds from the Securities Purchase Agreement were allocated to the equity instruments issued based on their relative fair values and recorded in additional paid-in capital. Shares of PIPE Preferred Stock, the conversion of which was approved at the Stockholders’ Meeting, convert into common stock at the option of the holder at the Preferred Conversion Rate, subject to certain ownership limitations as described below. The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions. Subject to limited exceptions, holders of shares of PIPE Preferred Stock will not have the right to convert any portion of their Preferred Stock if the holder, together with its affiliates, would beneficially own in excess of 4.99% (or up to 9.99% at the election of the holder) of the number of shares of the Company’s common stock outstanding immediately after giving effect to its conversion. Holders of PIPE Preferred Stock will be entitled to receive dividends on shares of PIPE Preferred Stock equal, on an as-if-converted-to-common stock basis, and in the same form as dividends actually paid on shares of the common stock. Except as otherwise required by law, the PIPE Preferred Stock does not have voting rights. The Company also entered into a registration rights agreement with the purchasers requiring the Company to register the resale of the shares of common stock, the shares issuable upon exercise of the Warrants and the shares issuable upon the conversion of the PIPE Preferred Stock. Placement Fees In connection with offerings completed by the Company in 2022, (the "2022 Offerings"), the Company entered into an agreement with a placement agent that, subject to satisfaction of the requirements contained therein, called for a placement fee payable based on capital raised from certain investors for a definitive time following the expiration of the agreement. The accrued placement fee of approximately $1.4 million related to the 2022 Offerings is included in accrued expenses in the consolidated balance sheets as of September 30, 2024. Additionally, the agreement called for the issuance of warrants with the following terms: Number of shares Exercise Price Expiration 3,300 $312.50 5 years 3,100 $175.00 5 years The warrants were valued on the date of the 2022 Offerings using the Black-Scholes model based on the following assumptions: Value ($ in millions) Expected Volatility Risk-Free Interest Rate Expected Dividend Yield Expected Term (years) $0.4 93.25% 1.81% 0% 5.0 $0.2 96.70% 2.87% 0% 5.0 September 2024 Public Offering On September 3, 2024, in connection with the September Public Offering (see Note 1), the Company sold an aggregate of 805,900 Common Stock Units and 2,773,000 Pre-Funded Warrant Units at a public offering price of $1.00 per Common Stock Unit and $0.9999 per Pre-Funded Warrant Unit. The Company received gross proceeds of approximately $3.6 million less underwriting discounts and commissions of $1.0 million, resulting in net proceeds of $2.6 million. Each Common Stock Unit consists of: (i) one share of the Company's Common Stock, (ii) a Series H Warrant to purchase one share of Common Stock at an exercise price of $1.00 per share that expires six months from the date of issuance, (iii) a Series I Warrant to purchase one share of Common Stock at an exercise price of $1.00 per share that expires eighteen months from the date of issuance, and (iv) a Series J Warrant to purchase one share of Common Stock at an exercise price of $1.00 per share that expires five years from the date of issuance. Each Pre-Funded Warrant Unit consists of: (i) a Pre-Funded Warrant to purchase one share of Common Stock at an exercise price of $0.0001 per share with no expiration date, (ii) one Series H Warrant, (iii) one Series I Warrant (iv) and one Series J Warrant. Pursuant to the Underwriting Agreement, the Company granted the Representative a 45-day Overallotment Option to purchase up to (i) 468,041 additional shares of Common Stock, (ii) 468,041 additional Series H Warrants, (iii) 468,041 additional Series I Warrants, and/or (iv) 468,041 additional Series J Warrants, solely to cover over-allotments. On August 30, 2024, the Underwriters partially exercised the Overallotment Option to purchase an additional 458,623 shares of Common Stock, 458,623 Series H Warrants, 458,623 Series I Warrants, and 458,623 Series J Warrants, or 458,623 Common Stock Units. The Common Stock Units issued through the exercise of the Overallotment Option are included in the 805,900 Common Stock Units noted above. The Overallotment Option expires on October 14, 2024, and is not expected to be exercised. The remaining balance of the Overallotment Option is not material to the condensed consolidated financial statements as of September 30, 2024. Furthermore, at the closing date, the Company agreed to deliver warrants to purchase an aggregate number of shares of Common Stock equal to 6% of the shares of Common Stock (i) issued in connection with the September 2024 Public Offering and (ii) issuable upon the exercise of the Pre-Funded Warrants. Therefore, the Company issued 214,734 warrants to the Representative and its designees (the “Representative Warrants”). The Representative Warrants are part of the underwriter costs and commissions incurred in connection with the September 2024 Public Offering. The Representative Warrants may be exercised to purchase one share of Common Stock at an exercise price of $1.55 per share and expires five years from the date of issuance. Each Series H Warrant, Series I Warrant, Series J Warrant (collectively, the “Series Warrants”), and Pre-Funded Warrant is immediately exercisable. The exercise price of the Series Warrants and Pre-Funded Warrants is subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting the Company’s Common Stock. Subject to limited exceptions, a holder of the Series Warrants will not have the right to exercise any portion of its Series Warrants if the holder (together with such holder’s affiliates) would beneficially own a number of shares of common stock in excess of 4.99% of the shares of Common Stock then outstanding (the “Beneficial Ownership Limitation”). Similarly, a holder of the Pre-Funded Warrants has a Beneficial Ownership Limitation of 9.99%. At the holder’s option, the holder of the Series Warrants may increase the beneficial ownership limitation to 19.99% of the shares of Common Stock then outstanding, with any such increase becoming effective upon 61 days’ prior notice to the Company. The Representative Warrants are exercisable after six months from the effective date of the Registration Statement filed by the Company on August 29, 2024. The Representative Warrants further have a Beneficial Ownership Limitation of 4.99%, which may be increased to 9.99% of the shares of Common Stock then outstanding at the option of the Representative. Any increase in the Beneficial Ownership Limitation will become effective upon 61 days’ prior notice to the Company. The Company assessed the Series Warrants, Pre-Funded Warrants, and Representative Warrants issued in connection with the September 2024 Public Offering (collectively, the “September 2024 Warrants”) and determined that they do not require liability classification pursuant to ASC 480. Furthermore, the September 2024 Warrants do not have any net cash settlement provisions that would preclude equity classification under ASC 815-40. Accordingly, the September 2024 Warrants were recorded to additional paid-in capital in the condensed consolidated balance sheets. Warrants The following table presents the number of common stock warrants outstanding: Warrants outstanding, December 31, 2023 1,104,217 Issued 13,724,435 Exercised (1,658,000 ) Expired — Warrants outstanding, September 30, 2024 13,170,652 As of September 30, 2024, and December 31, 2024, all warrants outstanding are recorded in additional paid-in capital in the condensed consolidated balance sheets. The following table presents the number and type of common stock warrants outstanding, their exercise price, and expiration dates as of September 30, 2024: Warrant Type Warrants Outstanding Exercise Price Expiration Date May 2020 Warrants 1,275 $ 5,625.00 5/20/2025 May 2020 Placement Agent Warrants 124 $ 7,031.25 5/20/2025 August 2020 Warrants 1,943 $ 4,375.00 8/3/2025 August 2020 Placement Agent Warrants 192 $ 5,468.75 7/30/2025 August 2021 Pharos Banker Warrants 148 $ 1,495.00 8/16/2026 February 2022 Series B Warrants 39,153 $ 140.00 2/4/2029 July 2022 Series C Warrants 28,404 $ 140.00 7/22/2027 January 2023 Series E Warrants 33,161 $ 40.00 3/21/2028 March 2023 Series F Warrants 499,909 $ 30.00 3/21/2025 March 2023 Series G Warrants 499,909 $ 30.00 3/21/2029 September 2024 Pre-Funded Warrants 1,115,000 $ 0.00 None September 2024 Series H Warrants 3,578,900 $ 1.00 3/3/2025 September 2024 Series I Warrants 3,578,900 $ 1.00 3/3/2026 September 2024 Series J Warrants 3,578,900 $ 1.00 9/3/2029 September 2024 Representative Warrants 214,734 $ 1.55 8/29/2029 13,170,652 As of September 30, 2024, the warrants issued by the Company had a weighted average exercise price of $5.29.

Preferred Stock

Preferred Stock	9 Months Ended
	Sep. 30, 2024
Preferred Stock
Preferred Stock	Note 14 . Preferred Stock Series X Convertible Preferred Stock As described in Note 3, Series X Convertible Preferred Stock has no voting rights prior to the conversion into common stock. While there are generally no voting rights of the Series X Convertible Preferred Stock, there are protective rights regarding the sales of the company, change of control, etc. Series X Preferred Stock may convert into common stock only if the Company’s common stock has been delisted from the NYSE American or has been approved for initial listing on the NYSE American or another stock exchange, at a rate of 100 shares of common stock for each share of Series X Convertible Preferred Stock. Other than dividends payable in shares of Common Stock, Holders of Series X Convertible Preferred Stock will be entitled to receive dividends on shares of Series X Convertible Preferred Stock equal, on an as-if-converted-to-common stock basis, and in the same form as dividends actually paid on shares of Common Stock. Upon consummation of the Merger, each holder of Old Catheter convertible promissory notes received, in exchange for discharge of the principal of his or its Notes, a number of shares of the Company's Series X Convertible Preferred Stock representing a potential right to convert into the Company's common stock in an amount equal to one common share for each $32.00 of principal amount. On March 21, 2023, the Company held the Stockholders' Meeting, at which the stockholders approved, among other things, the issuance of 199,359 shares of common stock upon the conversion of 1,993.581 of Series X Convertible Preferred Stock which were issued upon the closing of the Merger, see Note 3, Business Combination. On March 23, 2023, the Company issued 197,491 shares of common stock upon the conversion of 1,974.905 of Series X Convertible Preferred Stock. On October 24, 2023, the remaining 1,868 shares of common stock were issued upon the conversion of 18.676 shares of Series X Convertible Preferred Stock. The remaining 12,656.011 shares of Series X Convertible Preferred Stock are expected to remain outstanding until the Company meets the initial listing standards of the NYSE American or another national securities exchange or is delisted from the NYSE American, at which time they will convert into common stock. Series A Convertible Preferred Stock As described in Note 13, on January 9, 2023, the Company entered into a Securities Purchase Agreement for a Private Placement with the Investor. Pursuant to the Securities Purchase Agreement, shares of Series A Convertible Preferred Stock were issued, the conversion of which was approved at the Stockholders’ Meeting. The Series A Convertible Preferred Stock converts into common stock at the option of the holder at the Preferred Conversion Rate, subject to certain ownership limitations as described below. The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions. Subject to limited exceptions, holders of shares of Series A Convertible Preferred Stock will not have the right to convert any portion of their Series A Convertible Preferred Stock if the holder, together with its affiliates, would beneficially own in excess of 9.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to its conversion. Holders of Series A Convertible Preferred Stock will be entitled to receive dividends on shares of Series A Convertible Preferred Stock equal, on an as-if-converted-to-common stock basis, and in the same form as dividends actually paid on shares of the common stock. Except as otherwise required by law, the Series A Convertible Preferred Stock does not have voting rights. The Company also entered into a registration rights agreement with the purchasers requiring the Company to register the shares of common stock, issuable upon the conversion of the Series A Convertible Preferred Stock. The shares have been registered for resale on an effective registration statement on Form S-1. The following conversions of Series A Convertible Preferred Stock occurred subsequent to the issuance and prior to September 30, 2024: Date of Conversion Series A Shares Converted Common Shares Issued July 5, 2023 1,750 109,355 July 24, 2023 875 54,678 January 24, 2024 875 54,678 July 1, 2024 1,303 81,423 July 11, 2024 1,000 62,489 July 22, 2024 1,000 62,500 July 23, 2024 400 25,000 Each share of Series A Convertible Preferred Stock is convertible into approximately 62.5 shares of common stock. The common stock was issued pursuant to the exemption contained in Section 3(a)(9) of the Securities Act of 1933, as amended (the “Act”), which applies to transactions in which a security is exchanged by an issuer with its existing security holders exclusively where no commission or other remuneration is paid or given directly or indirectly for soliciting such exchange. The shares issued have been registered for resale on an effective registration statement on Form S-1. After the final conversion on July 23, 2024, the Company had no shares of Series A Convertible Preferred Stock outstanding.

StockBased Compensation

StockBased Compensation	9 Months Ended
	Sep. 30, 2024
StockBased Compensation
Stock-Based Compensation	Note 15. Stock-Based Compensation 2018 Equity Incentive Plan In September 2018, the Company’s board of directors adopted, and the Company’s stockholders approved, the 2018 Equity Incentive Plan (the “2018 Plan”) which provided for the grant of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock units, performance-based stock awards and other forms of equity compensation to the Company’s employees, directors and consultants. In July 2023, the 2018 Plan was replaced by the 2023 Equity Incentive Plan (the "2023 Plan"), as described below. As of July 2023, no additional awards could be made under the 2018 Plan and no shares of common stock were reserved for future issuance. As of September 30, 2024, there are 7 non-statutory stock options outstanding under the 2018 Plan. Three expire in June 2028 and four expire in January 2030. 2018 Employee Stock Purchase Plan In September 2018, the Company adopted the 2018 Employee Stock Purchase Plan (the “ESPP”) which permitted eligible employees to purchase the Company’s common stock at a discount through payroll deductions during defined offering periods. Eligible employees could elect to withhold up to 15% of their base earnings to purchase shares of the Company’s common stock at a price equal to 85% of the fair market value on the first day of the offering period or the purchase date, whichever was lower. The number of shares of common stock reserved for issuance under the ESPP automatically increased on January 1 of each fiscal year by the lesser of (1) 23 shares, (2) 1.25% of the total number of shares outstanding on December 31 of the preceding fiscal year, or (3) such other amount as the Company’s board of directors may determine. In April 2024, the Company formally terminated the ESPP. For the three and nine months ended September 30, 2024 and 2023, no cash was received from the exercise of purchase rights under the ESPP in each respective period. As of September 30, 2024, the Company had issued 95 shares of common stock since inception of the ESPP, and no shares were reserved for future issuance. As of December 31, 2023, the Company had issued 95 shares of common stock since inception of the ESPP, and 2 shares were reserved for future issuance. Upon termination of the ESPP in April 2024, the reserved shares were released back to the authorized pool. 2020 Inducement Equity Incentive Plan In March 2020, the Company adopted the 2020 Inducement Equity Incentive Plan (the “2020 Plan”) for the purpose of attracting, retaining and incentivizing employees in furtherance of the Company’s success. The 2020 Plan was adopted without stockholder approval pursuant to Rule 303A.08 of the New York Stock Exchange. The 2020 Plan is used to offer equity awards as material inducements for new employees to join the Company. Upon adoption of the 2020 Plan, 64 shares of common stock were reserved for the granting of inducement stock options, restricted stock awards, restricted stock units and other forms of equity awards. As of September 30, 2024 and December 31, 2023, zero and 54 shares of common stock were reserved for future issuance under the 2020 Plan. In April 2024, the Company terminated the 2020 Plan at which time the reserved shares were released back to the authorized pool. Stock Options Assumed in Merger (See Note 3, Business Combination) At the closing of the Merger, each outstanding option to purchase Old Catheter common stock that had not previously been exercised prior to the closing of the Merger was assumed and converted into options to purchase 75,365 shares of the Company’s common stock (“Replacement Options”). Additionally, no Old Catheter options were amended in connection with the Merger. All the Replacement Options vested in accordance with the original terms of the grants in place at the time of the Merger. As a result, $3.4 million of purchase price consideration, which represented the estimated fair value of Old Catheter’s assumed stock options, and $1.1 million of stock-based compensation expense, which represents the excess of the estimated fair value of the Replacement Options over the assumed Old Catheter stock options, were recognized upon the closing of the Merger. 2023 Equity Incentive Plan In July 2023, the Company’s stockholders approved, the 2023 Plan, as defined above, which provided for the grant of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock units, performance-based stock awards and other forms of equity compensation to the Company’s employees, directors and consultants. Stock options granted under the 2023 Plan to employees and consultants generally will vest annually over a five-year period or as determined by the Board’s Compensation Committee, while grants to non-employee directors generally vest quarterly over a three-year period. As of September 30, 2024 and December 31, 2023, 225,085 and 50,186 shares of common stock were reserved for future issuance pursuant to the 2023 Plan. The number of shares available for issuance under the 2023 Plan also includes a quarterly increase commencing on September 1, 2023 by an amount equal to the lesser of (i) 10% of the number equal to the number of shares of common stock outstanding on the applicable adjustment date less the number of shares of common stock outstanding at the beginning of the fiscal quarter immediately preceding the adjustment date, but if such number is a negative number, then the increase will be zero; or (ii) such lesser number of shares as may be determined by the Board. On January 8, 2024, the Board approved the issuance of a total of 28,500 non-qualified stock options under the 2023 Plan. 7,500 of these non-qualified options were issued to non-employee directors that vest at 8 1/3% per quarter for 3 years with an exercise price of $4.00 and expiration date of January 8, 2034. The remaining 21,000 non-qualified options were issued to employees and consultants and vest at 20% per year for 5 years with an exercise price of $4.00 and expiration date of January 8, 2034. On February 26, 2024, the Board approved the issuance of a total of 15,000 incentive stock options under the 2023 Plan. All options were issued to employees and vest at 20% per year for 5 years with an exercise price of $4.20 and expiration date of February 26, 2034. On April 24, 2024, the Board approved the issuance of a total of 12,500 incentive stock options under the 2023 Plan. All options were issued to employees and vest at 20% per year for 5 years with an exercise price of $4.60 and expiration date of April 24, 2034. On July 9, 2024, the Board approved the issuance of a total of 10,000 incentive stock options under the 2023 Plan. All options were issued to employees and vest at 20% per year for 5 years with an exercise price of $3.50 and expiration date of July 9, 2034. The options issued during the three and nine months ended September 30, 2024 were valued at approximately $262 thousand using the Black-Scholes model based on the following assumptions on the date of issue: Non-Employee Director Options Issued January 8, 2024 Employee Options Issued January 8, 2024 Employee Options Issued February 26, 2024 Employee Options Issued April 24, 2024 Employee Options Issued July 9, 2024 Risk-free interest rate 4.01 % 4.01 % 4.28 % 4.65 % 4.30 % Volatility 175.36 % 175.36 % 178.14 % 211.61 % 214.61 % Expected dividend yield 0 % 0 % 0 % 0 % 0 % Expected life (in years) 6.5 6.5 6.5 6.5 6.5 Non-Plan Options Issued On April 24, 2024, the Board approved the issuance of a total of 25,000 Non-Plan Options as an employment incentive for the position of Chief Commercial Officer. The options were issued on May 1, 2024, the first day of employment and vest at 20% per year for 5 years with an exercise price of $5.321 and an expiration date of May 1, 2034. The non plan options issued were valued at approximately $131 thousand using the Black-Scholes model based on the following assumptions on the date of issue: Non-Plan Options Issued May 1, 2024 Risk-free interest rate 4.63 % Volatility 211.61 % Expected dividend yield 0 % Expected life (in years) 6.5 The following is a summary of stock option activity for the nine months ended September 30, 2024: Stock Options Weighted Average Exercise Price Weighted Average Remaining Life (in years) Aggregate Intrinsic Value (in thousands) Outstanding at December 31, 2023 21,465 $ 64.71 6.38 $ — Options exercised — $ — — — Options granted 91,000 $ 4.42 — — Cancelled/forfeited (16,652 ) $ 4.50 — — Outstanding at September 30, 2024 95,813 $ 17.92 8.86 $ 4,510.00 Vested and expected to vest at September 30, 2024 95,813 $ 17.92 8.86 $ 4,510.00 Exercisable at September 30, 2024 18,148 $ 75.35 6.07 $ — Restricted Stock Units All restricted stock units have been forfeited or vested as of December 31, 2023. Restricted Stock Awards All restricted stock awards have been forfeited or vested as of December 31, 2023. Stock-based compensation expense for the three and nine months ended September 30, 2024 was $17 thousand and $36 thousand, respectively, in selling, general and administrative expenses in the condensed consolidated statements of operations. Stock-based compensation expense for the three and nine months ended September 30, 2023 was $2 thousand and $1.2 million respectively, in the Company's condensed consolidated statements of operations. Total unrecognized estimated stock-based compensation expense by award type and the remaining weighted average recognition period over which such expense is expected to be recognized at September 30, 2024 was as follows: Unrecognized Expense (in thousands) Remaining Weighted Average Recognition Period (in years) Stock options $ 309 4.4 Restricted stock awards $ — — Restricted stock units $ — —

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2024
Income Taxes
Income Taxes	Note 16. Income Taxes The provision for income taxes for interim periods is determined using an estimated annual effective tax rate. The effective tax rate may be subject to fluctuations during the year as new information is obtained, which may affect the assumptions used to estimate the annual effective tax rate, including factors such as valuation allowances against deferred tax assets, the recognition or de-recognition of tax benefits related to uncertain tax positions, if any, and changes in or the interpretation of tax laws in jurisdictions where the Company conducts business. For the three and nine months ended September 30, 2024 and 2023, the Company did not record any federal or state income tax provision or benefit due to net losses incurred for all periods presented. The Company’s net deferred tax assets generated mainly from net operating losses are fully offset by a valuation allowance as the Company believes it is not more likely than not that the benefit will be realized. The Company will continue to assess its position in future periods to determine if it is appropriate to reduce a portion of its valuation allowance in the future. As of September 30, 2024, the Company has an open sales and use tax audit with the California Department of Tax and Fee Administration covering the period from October 1, 2020 through March 31, 2023.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2024
Commitments and Contingencies
Commitments and Contingencies	Note 17. Commitments and Contingencies In the normal course of business, the Company is at times subject to pending and threatened legal actions. In management’s opinion, any potential loss resulting from the resolution of these matters will not have a material effect on the results of operations, financial position or cash flows of the Company. As of September 30, 2024, the Company had no outstanding litigation.

Employee Benefit Plan

Employee Benefit Plan	9 Months Ended
	Sep. 30, 2024
Employee Benefit Plan
Employee Benefit Plan	Note 18. Employee Benefit Plan In January 2019, the Company established a defined contribution plan under Section 401(k) of the Internal Revenue Code (“401(k) Plan”). Under the terms of the 401(k) Plan, all full-time employees were eligible to make voluntary contributions as a percentage or defined amount of compensation. The Company made matching contributions based on 100% of each employee’s contribution up to 3% and 50% of contributions between 3% and 5%, with the match-eligible contribution limited to 4% of the employee’s eligible compensation. The Company cancelled the 401(k) Plan effective March 10, 2023 and distributed all assets held by the 401(k) Plan to the participants. The Company had no expenses related to the matching contributions for the three and nine months ended September 30, 2024 and 2023.

Related Parties

Related Parties	9 Months Ended
	Sep. 30, 2024
Related Parties
Related Parties	Note 19. Related Parties Prior to the Merger, David A. Jenkins, the Company’s current Executive Chairman of the Board and Chief Executive Officer, and Old Catheter’s then Chairman of the Board of Directors, and his affiliates held approximately $25.1 million of Old Catheter’s Convertible Promissory Notes, or the Notes, that were converted in the Old Catheter merger into 7,856.251 shares of Series X Convertible Preferred Stock (see Note 3, Business Combination, and Note 14, Preferred Stock). In consideration for forgiving the interest accrued but remaining unpaid under the Notes in an aggregate amount of approximately $13.9 million, Mr. Jenkins and his affiliates also received royalty rights equal to approximately 12% of the net sales, if any, of LockeT, commencing upon the first commercial sale and through December 31, 2035 (see Note 10, Royalties Payable). In addition to the shares described above that were issued in connection with the Notes, Mr. Jenkins and his affiliates received 1,325.838 shares of Series X Convertible Preferred Stock in the merger, and Mr. Jenkins’ adult children received 1,284.344 shares of Series X Convertible Preferred Stock in the merger, all in exchange for their equity interests in Old Catheter in accordance with the merger exchange ratio. In connection with the Merger (see Note 3, Business Combination), the Company assumed $1.4 million of accrued expenses and advances, of which $1.1 million was due to Mr. Jenkins and was paid on January 10, 2023. Mr. Jenkins’ daughter, the Company’s non-executive Chief Operating Officer, received options to purchase 14,416 shares of the Company’s common stock upon the closing of the merger in exchange for her options to purchase shares of Old Catheter common stock, converted based on the exchange ratio in the merger. Of the total options to purchase 14,416 shares of the Company’s common stock, 14,081 options have an exercise price of $5.90 per share, and the remaining 335 options have an exercise price of $20.20 per share. Margrit Thomassen, the Company’s Interim Chief Financial Officer, received options to purchase 1,676 shares of the Company’s common stock upon the closing of the merger in exchange for her options to purchase shares of Old Catheter common stock, converted based on the exchange ratio in the merger. The options have an exercise price of $5.90 per share. In January 2024, she received an option to purchase 2,500 shares of the Company’s common stock under the 2023 Plan. The options have an exercise price of $4.00 per share, vest at 20% per year for 5 years and expire in January 2034. Following stockholder approval on March 21, 2023, the Company issued 99,182 shares of common stock to Mr. Jenkins and affiliates upon conversion of 991.828 shares of Series X Convertible Preferred Stock, and 23,532 shares of common stock to his adult children upon conversion of 235.320 shares of Series X Convertible Preferred Stock. On May 1, 2024, Marie-Claude Jacques, the Company’s Chief Commercial Officer, received a non-plan option to purchase 25,000 shares of the Company’s common stock. The options have an exercise price of $5.321 per share, vest at 20% per year for 5 years and expire in May 2034. During the three months ended September 30, 2024, the Company entered into various short-term promissory notes with various related parties (the “Related Party Notes”). These Related Party Notes had a maturity date of August 30, 2024 and interest rates of 8% per annum. On August 23, 2024, the Notes were amended to extend the maturity date to January 31, 2026 and increase the interest rate to 12% per annum effective August 31, 2024. See Note 9, Notes Payable for further information. The related parties and the amounts owed to each related party are summarized in the following table (in thousands): Related Party Issuance Date Principal Amount Interest Paid Interest Accrued David Jenkins 5/30/2024 $ 500 $ 10 $ 5 FatBoy Capital 6/25/2024 $ 150 $ 2 $ 2 FatBoy Capital 7/1/2024 $ 250 $ 3 $ 3 FatBoy Capital 7/18/2024 $ 100 $ 1 $ 1 Jenkins Family Charitable Institute 7/25/2024 $ 500 $ 4 $ 5 On September 3, 2024, the Jenkins Family Charitable Institute also invested approximately $500,000 in the Company’s public offering and received 265,000 shares of common stock; 235,000 pre funded warrants with an exercise price of $0.0001 and no expiration date; 500,000 Series H Warrants with an exercise price of $1.00 per share that expire on March 3, 2025; 500,000 Series I Warrants with an exercise price of $1.00 per share that expire on March 3, 2026; and 500,000 Series J Warrants with an exercise price of $1.00 per share that expire on September 3, 2029.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2024
Subsequent Events
Subsequent Events	Note 20. Subsequent Events 2024 Warrant Inducement Offer On October 24, 2024, the Company executed the 2024 Inducement Offer with certain holders of the Existing Warrants. The Existing Warrants had exercise prices ranging from $1.00 to $40.00 per share. Following the closing of the 2024 Inducement Offer, such holders immediately exercised an aggregate of (i) 33,160.8 Series E Warrants, (ii) 499,909.34 Series F Warrants, (iii) 499,909.34 Series G Warrants, (iv) 1,990,000 Series H Warrants, and (v) 2,325,000 Series I Warrants to purchase up to 5.3 million shares of Common Stock at a reduced exercise price of $0.70 per share. In consideration for the immediate exercise of the Existing Warrants for cash, the Company issued unregistered new Series K Common Stock Purchase Warrants (“Series K Warrants”) to purchase up to a number of shares equal to 200% of the number of shares of Common Stock issued pursuant to the exercise of the Existing Warrants. The Series K Warrants have an exercise price of $0.70 per share, a term of 5.5 years following stockholder approval, and are not exercisable until such approval is obtained. As additional consideration, the company issued placement agent warrants to purchase up to 320,879 shares of common stock on the same terms as the Series K warrants, except the exercise price is $1.085 per share and have a termination date of October 28, 2029. The Company received aggregate gross proceeds of approximately $3.7 million in cash from the exercise of the Existing Warrants pursuant to the 2024 Inducement Offer, prior to deducting placement agent fees and offering expenses of $0.4 million. As of the date of the 2024 Inducement Offer, 578,900 Series H and 1,078,900 Series I warrants remained unexercised. Prior to the repricing and execution of the 2024 Inducement Offer, the Company received additional gross proceeds of approximately $1.2 million from the exercise of 1,010,000 Series H Warrants and 175,000 Series I Warrants in accordance with their original terms (as summarized below). Issuance of Securities from Warrant Exercises Aside from the common stock issued in connection with the 2024 Warrant Inducement Offer, the Company also issued common stock in connection with the following exercises of warrants (in thousands): Name of Warrant Exercise Date Issue Date Shares Common Stock Issued Number of Warrants Exercised Proceeds September 2024 Pre-Funded Warrant 10/3/2024 10/4/2024 250,000 250,000 $ — September 2024 Pre-Funded Warrant 10/16/2024 10/16/2024 196,000 196,000 $ — September 2024 Pre-Funded Warrant 10/18/2024 10/21/2024 434,000 434,000 $ — September 2024 Series H Warrant 10/18/2024 10/21/2024 1,010,000 1,010,000 $ 1,010 September 2024 Series I Warrant 10/18/2024 10/21/2024 175,000 175,000 $ 175 September 2024 Pre-Funded Warrant 10/29/2024 10/29/2024 235,000 235,000 $ —

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2024
Summary of Significant Accounting Policies
Principles of Consolidation	The unaudited condensed consolidated financial statements of the Company include the accounts of the Company and Old Catheter. All intercompany transactions have been eliminated in consolidation.
Basis of Presentation	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP"). The Financial Accounting Standards Board (“FASB”) establishes these principles to ensure financial condition, results of operations, and cash flows are consistently reported. Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative nongovernmental GAAP as found in the FASB Accounting Standards Codification ("ASC"). Certain footnotes and other financial information normally required by U.S. GAAP have been condensed or omitted in accordance with instructions to Form 10-Q and Article 8 of Regulation S-X. In the opinion of management, such statements include all adjustments which are considered necessary for fair presentation of the unaudited condensed consolidated financial statements of the Company. The operating results presented herein are not necessarily an indication of the results that may be expected for the year. The unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited Consolidated Financial Statements included in its Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (“SEC”) on April 1, 2024.
Use of Estimates	The preparation of the unaudited condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results may differ materially from those estimates. The Company’s unaudited condensed consolidated financial statements are based upon a number of estimates including, but not limited to, the accounting for the Old Catheter business combination (see Note 3, Business Combination), allowance for credit losses, evaluation of impairment of long-lived assets and goodwill, valuation of long-lived assets and their associated estimated useful lives, reserves for warranty costs, fair value of royalties payable, evaluation of probable loss contingencies, fair value of preferred stock and warrants issued, and the fair value of equity awards granted.
Concentrations of Credit Risk	The Company's financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. Cash equivalents represent short-term, highly liquid investments with maturities of 90 days or less at the date of purchase. The Company generally maintains balances in various operating accounts at financial institutions that management believes to be of high credit quality, in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its cash and cash equivalents and does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company has no significant off-balance sheet risk such as foreign exchange contracts, option contracts, or other hedging arrangements. The Company extends credit to customers in the normal course of business. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the condensed consolidated financial statements. The Company does not require collateral from its customers to secure accounts receivable. The Company had three and five customers that represented 90% and 86% of the Company's consolidated revenue for the three and nine months ended September 30, 2024, respectively; and three and four customers that represented 71% and 73% of the Company's consolidated revenue for the three and nine months ended September 30, 2023, respectively.
Reclassifications	Certain prior year financial statement amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on our previously reported results of operations or accumulated deficit.
Segment Reporting	The Company’s Board of Directors and executive management team represents the entity’s chief operating decision makers. To date, the Company’s executive management team has viewed the Company’s operations as one segment that includes the marketing, sales, and development of medical technologies in the field of cardiac electrophysiology. As a result, the financial information disclosed materially represents all of the financial information related to the Company’s sole operating segment.
Cash and Cash Equivalents	Cash equivalents primarily represent funds invested in readily available checking and money market accounts. The Company maintains deposits in financial institutions in excess of federally insured limits of $250,000, in the amount of $987 thousand at September 30, 2024.
Fair Value Measurements	Fair value represents the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants and is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. A three-tier fair value hierarchy is used to identify inputs used in measuring fair value as follows: Level 1 - Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets; Level 2 - Inputs other than the quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and Level 3 - Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions. Cash equivalents, prepaid expenses, trade accounts receivable, accounts payable, and accrued expenses are reported on the condensed consolidated balance sheets at carrying value which approximates fair value due to the short-term maturities of these instruments. The following table details the fair value measurements within the fair value hierarchy of the Company’s financial instruments: Fair value at September 30, 2024 Total Level 1 Level 2 Level 3 Assets: Cash Equivalents Mutual Funds $ 1,237 $ 1,237 $ — $ — Money Market Funds 18 18 — — Total assets $ 1,255 $ 1,255 $ — $ — Liabilities Royalties payable $ 9,797 $ — $ — $ 9,797 Total liabilities $ 9,797 $ — $ — $ 9,797 Fair value at December 31, 2023 Total Level 1 Level 2 Level 3 Assets: Cash Equivalents Mutual Funds $ 3,397 $ 3,397 $ — $ — Money Market Funds 10 10 — — Total assets $ 3,407 $ 3,407 $ — $ — Liabilities Royalties payable $ 6,974 $ — $ — $ 6,974 Total liabilities $ 6,974 $ — $ — $ 6,974 The royalties payable have significant unobservable inputs that are not supported by any market data. As such, the Company developed its own assumptions and identified the inputs as Level 3. The revenue adjusted discount rate (“RADR”) was calculated using a weighted average cost of capital (“WACC”) approach for the measurement of the Level 3 liability. The RADR considers the WACC from the Company’s impairment analysis and adjusts certain inputs to represent the risk profile of the revenue. Under the cost of equity section, the risk-free rate has changed to be commensurate with the royalties payable term. Additionally, the Beta and Company Specific Risk Premium have been adjusted to Revenue Beta and Revenue Specific Risk Premium, respectively. This adjustment was calculated by multiplying the respective metric by the quotient of equity volatility over revenue volatility. The remaining inputs from the Impairment WACC have remained unchanged. The following table summarizes the significant unobservable inputs used in the fair value measurement of Level 3 instruments as of September 30, 2024 and December 31, 2023: September 30, 2024 Instrument Valuation Technique Unobservable Input Input Range Royalties Payable Discounted future cash flows Revenue adjusted discount rate 20% December 31, 2023 Instrument Valuation Technique Unobservable Input Input Range Royalties Payable Discounted future cash flows Revenue adjusted discount rate 28% Increases or decreases in the fair value of the royalties payable can result from updates to assumptions, such as changes in discount rates, project cash flows, among other assumptions. Judgment is used in determining these assumptions as of the initial valuation date and at each subsequent reporting period. Changes or updates to assumptions could have a material impact on the reported fair value, the change in fair value, and the results of operations in any given period.
Accounts Receivable and Allowances for Credit Losses	Under the Current Expected Credit Loss ("CECL") impairment model, the Company develops and documents its allowance for credit losses on its trade receivables based on three portfolio segments: Hospitals - United States, Hospitals - Europe, and Distributors. The determination of portfolio segments is based primarily on the customers’ industry and geographical location. Trade accounts receivable are recorded at invoiced amounts, net of allowance for credit losses, if applicable, and are unsecured and do not bear interest. The allowance for credit losses is based on the probability of future collection under the CECL impairment model in which the Company determines its estimated loss rates based on an aging schedule. The Company also considers reasonable and supportable current information in determining its estimated loss rates, such as external forecasts, macroeconomic trends or other factors, including customers’ credit risk and historical loss experience. The adequacy of the allowance is evaluated on a regular basis. Trade account balances are written off after all means of collection are exhausted and the balance is deemed uncollectible. Subsequent recoveries are credited to the allowance for credit losses, if any. Changes in the allowance are recorded as adjustments to bad debt expense in the period incurred. The allowance for credit losses within trade accounts receivable was not material as of September 30, 2024 and December 31, 2023.
Inventories	Inventories are stated at the lower of cost (determined by the first-in, first-out method) or net realizable value. Cost includes materials, labor, and manufacturing overhead related to the purchase and production of inventories. The Company reduces the carrying value of inventories for those items that are potentially in excess, obsolete or slow-moving based on changes in customer demand, technological developments or other economic factors.
Property and Equipment	Property and equipment are recorded at cost and depreciated on a straight-line basis over their estimated useful lives as follows: Machinery and equipment 2-5 years Computer hardware and software 1-5 years LockeT animation video 3 years VIVO DEMO/Clinical Systems 1-5 years Leasehold improvements are depreciated over the shorter of the useful life of the leasehold improvement or the term of the underlying property’s lease. The Company periodically reviews the residual values and estimated useful lives of each class of its property and equipment for ongoing reasonableness, considering long-term views on its intended use of each class of property and equipment and the planned level of improvements to maintain and enhance assets within those classes. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the account balances and any resulting gain or loss is recognized in income for the period. The cost of repairs and maintenance is expensed as incurred, whereas significant betterments are capitalized.
Impairment of Long-lived Assets	In accordance with ASC 360, Impairment and Disposals of Long-lived Assets The Company concluded there was no impairment as of September 30, 2024.
Goodwill	In accordance with ASC 350, Intangibles – Goodwill and Other To determine whether goodwill is impaired, annually or more frequently if needed, the Company performs a multi-step impairment test. The Company first has the option to assess qualitative factors to determine if it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value. The Company may also elect to skip the qualitative testing and proceed directly to the quantitative testing. When performing quantitative testing, the Company first estimates the fair values of its reporting units using a combination of an income and market approach. To determine fair values, the Company is required to make assumptions about a wide variety of internal and external factors. Significant assumptions used in the impairment analysis include financial projections of free cash flow (including significant assumptions about operations, including the rate of future revenue growth, capital requirements, and income taxes), long-term growth rates for determining terminal value and discount rates. Comparative market multiples are used to corroborate the results of the discounted cash flow test. These assumptions require significant judgment. Pursuant to ASU 2017-04, Simplifying the Test for Goodwill Impairment
Royalties Payable	The Company is obligated to pay royalties under various royalty agreements executed by Old Catheter. On January 9, 2023, prior to the consummation of the Merger, Old Catheter entered in an agreement with its Convertible Promissory Noteholders (“Noteholders”), which substantially consisted of amounts due to David A. Jenkins, previously Old Catheter's Chairman of the Board of Directors, and, currently, the Company’s Executive Chairman of the Board of Directors and Chief Executive Officer, to forgive all accrued interest and future interest expense in exchange for a future royalty right. The Company will pay to the Noteholders a royalty equal to 11.82% of net sales of LockeT, commencing on the first commercial sale through December 31, 2035 (see Note 10, Royalties Payable). The Company recognizes a current liability for royalty fees incurred and payable to the Noteholders based on actual sales of LockeT devices. The liability is recorded as current portion of royalties payable in the condensed consolidated balance sheet. The Company further recognizes a liability for future, estimated royalty payments to the Noteholders at fair value, which is recorded as royalties payable in the condensed consolidated balance sheet (the “Royalties Payable”). The fair value of the Royalties Payable is an estimate that is based on the projected sales of LockeT through the end of 2035. The projected sales are then multiplied by the royalty rate of 11.82% and discounted back to their present value using the RADR. At each reporting date, the fair value of the Royalty Payable is re-measured in connection with any changes to Management’s projections as a change in estimate.
Product Warranty	The Company offers product warranties against defects in material and workmanship when properly the products are used for their intended purpose and properly maintained. Warranty expenses are included in cost of revenues in the accompanying unaudited condensed consolidated statements of operations. Changes in estimates to previously established warranty accruals result from current period updates to assumptions regarding repair and product recall costs and are included in current period warranty expense. As of September 30, 2024 and December 31, 2023, there was no accrued warranty balance.
Distinguishing Liabilities from Equity	The Company evaluates equity or liability classification for freestanding financial instruments, including convertible preferred stock, warrants, and options, pursuant to the guidance under ASC Topic 480 , Distinguishing Liabilities from Equity If a freestanding financial instrument does not represent an outstanding equity share and does not meet liability classification under ASC 480, the Company then assesses whether the freestanding financial instrument is indexed to its own stock and meets equity classification pursuant to ASC 815-40, Derivatives and Hedging
Revenue Recognition	In accordance with ASC Topic 606, Revenue from Contracts with Customers Pursuant to ASC 606, the Company applies the following five steps to each customer contract: Step 1: Identify the contract with the customer Step 2: Identify the performance obligations in the contract Step 3: Determine the transaction price in the contract Step 4: Allocate the transaction price to the performance obligations in the contract Step 5: Recognize revenue when the Company satisfies a performance obligation VIVO System The VIVO System offers 3D cardiac mapping to help localize the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to electrophysiology studies. Customers are provided with VIVO Positioning Patch Sets, which are custom patches, that are used in conjunction with the VIVO System. The VIVO Positioning Patch Sets are integral to the functionality of the VIVO System. The VIVO System, including the VIVO Positioning Patch Sets, represents the Company’s primary performance obligation. The Company recognizes revenue when physical possession and control of the VIVO System is transferred to the customer upon delivery. The Company also offers customers software upgrades for the VIVO System, which may be purchased and paid in advance at contract inception. Software upgrades represent stand-ready services, whereby the Company promises to provide software upgrades to the customer when and as upgrades are available. Software upgrade services may be offered for initial contract terms of one to multiple years. Customers have the option to renew terms for software upgrades services at the end of each term. The software upgrade services represent the Company's second performance obligation, which is recognized evenly over time over the contract term. The Company invoices the customer after physical possession and control of the VIVO System is transferred to the customer and recognizes revenue upon delivery. The timing of payment for the corresponding invoices is dependent upon the credit terms identified in each contract. The Company invoices customers who pay for software upgrades in advance in conjunction with the invoice for the delivery of the VIVO System, and subsequent renewals of software upgrades are invoiced at the inception of the term. Revenue for these stand-ready services is recognized evenly over the term of the upgrade period, consistently with similar stand-ready services under ASC 606. Similar to the delivery of the VIVO System, the timing of payment for the corresponding invoices is dependent upon the credit terms identified in each contract. Revenue is recognized at the point in time that the product is delivered to the customer. LockeT LockeT was launched by the Company in February 2023 and is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure. LockeT is intended to temporarily secure sutures and aid clinicians in locating and removing sutures efficiently. The LockeT device represents a performance obligation in the customer contract. The Company recognizes revenue when it transfers control of the LockeT device to the customer, which happens when the Company delivers the product to the customer. For both LockeT and VIVO System, the Company has elected the practical expedient to expense costs incurred to obtain a contract, rather than recognizing these costs as an asset at the time of occurrence. Disaggregation of Revenue The following table summarizes disaggregated product sales by geographic area (in thousands): For the Three Months Ended September 30, For the Nine Months Ended September 30, 2024 2023 2024 2023 Product Sales US $ 62 $ 110 $ 129 $ 241 Europe 34 23 142 73 $ 96 $ 133 $ 271 $ 314
Shipping and Handling Costs	Shipping and handling costs charged to customers are included in net product sales, while all other shipping and handling costs are included in selling, general and administrative expenses in the accompanying unaudited condensed consolidated statements of operations.
Advertising and Marketing	Advertising costs are expensed as incurred and included in selling, general and administrative expenses. Advertising costs were $31 thousand and $127 thousand during the three and nine months ended September 30, 2024, respectively. Advertising costs were $309 thousand and $914 thousand during the three and nine months ended September 30, 2023, respectively.
Patents	The Company expenses patent costs, including related legal costs, as incurred and records such costs as selling, general and administrative expenses in the accompanying unaudited condensed consolidated statements of operations.
Research and Development	Major components of research and development costs include consulting, research grants, supplies and clinical trial expenses. Research and development expenses are charged to operations in the period incurred.
Stock-based Compensation	The Company records stock-based compensation expense associated with stock options, restricted stock awards (“RSAs”) and restricted stock units (“RSUs”) issued to employees, members of the Company’s board of directors and consultants in accordance with the guidance under ASC Topic 718 , Compensation – Stock Compensation As a result of the Merger, all unvested Old Catheter stock options were subject to accelerated vesting and became fully vested as of the closing date of the business combination. The Company recognized the fair value of the replacement options as included in consideration transferred to the extent they do not exceed the fair value of the equivalent Old Catheter options. Any incremental fair value was recognized in compensation expense in the post-combination period, with this recognized as a Day 1 expense due to the Old Catheter options becoming fully vested concurrent with the closing of the business combination.
Income Taxes	The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using enacted tax rates and laws that are expected to be in effect when the differences reverse. Any resulting net deferred tax assets are evaluated for recoverability and, accordingly, a valuation allowance is provided when it is more likely than not that all or some portion of the deferred tax asset will not be realized. The Company accounts for uncertainty in income taxes using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining whether it is more likely than not that the position will be sustained on an audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. An uncertain tax position is considered effectively settled on completion of an examination by a taxing authority if certain other conditions are satisfied. Should the Company incur interest and penalties relating to tax uncertainties, such amounts would be classified as a component of interest expense and other expense, respectively.
Basic and Diluted Net Loss per Share of Common Stock	Earnings per share attributable to common stockholders is calculated using the two-class method, which is an earnings allocation formula that determines earnings per share for the holders of the Company’s common shares and participating securities. The Company’s Series A Convertible Preferred Stock, Series X Convertible Preferred Stock, and outstanding warrants contain participating rights in distributions made to common stockholders and, therefore, are participating securities. The Company did not declare nor pay any dividends nor distributions in the current period. Furthermore, the participating securities do not include a contractual obligation to share in the losses of the Company and are not included in the calculation of net loss per share in the periods that have a net loss. In addition, common stock equivalent shares (whether or not participating) are excluded from the computation of diluted earnings per share in periods in which they have an anti-dilutive effect on net loss per common share. Diluted net loss per share is computed using the more dilutive of (a) the two-class method or (b) the if-converted method and treasury stock method, as applicable. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. Diluted net loss per share is equivalent to basic net loss per share for the periods presented herein because common stock equivalent shares from warrants, stock options, non-vested restricted stock awards, restricted stock units, Series A Convertible Preferred Stock, and Series X Convertible Preferred Stock were antidilutive (see Note 12, Net Loss per Share). Net loss attributable to common stockholders consists of net income or loss, as adjusted for actual and deemed dividends declared. The Company recorded a deemed dividend for the modification of existing warrants and issuance of new warrants during the three and nine months ended September 30, 2023 of $0 and $0.8 million, respectively. The deemed dividend is added to the net loss in determining the net loss available to common stockholders for the three and nine months ended September 30, 2023. There was no deemed dividend for the three and nine months ended September 30, 2024.
Recently Announced Accounting Pronouncements	In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2024
Summary of Significant Accounting Policies
Schedule of the fair value measurements within the fair value hierarchy of the Company's financial instruments	Fair value at September 30, 2024 Total Level 1 Level 2 Level 3 Assets: Cash Equivalents Mutual Funds $ 1,237 $ 1,237 $ — $ — Money Market Funds 18 18 — — Total assets $ 1,255 $ 1,255 $ — $ — Liabilities Royalties payable $ 9,797 $ — $ — $ 9,797 Total liabilities $ 9,797 $ — $ — $ 9,797 Fair value at December 31, 2023 Total Level 1 Level 2 Level 3 Assets: Cash Equivalents Mutual Funds $ 3,397 $ 3,397 $ — $ — Money Market Funds 10 10 — — Total assets $ 3,407 $ 3,407 $ — $ — Liabilities Royalties payable $ 6,974 $ — $ — $ 6,974 Total liabilities $ 6,974 $ — $ — $ 6,974
Schedule of Significant unobservable inputs used in the fair value measurement	September 30, 2024 Instrument Valuation Technique Unobservable Input Input Range Royalties Payable Discounted future cash flows Revenue adjusted discount rate 20% December 31, 2023 Instrument Valuation Technique Unobservable Input Input Range Royalties Payable Discounted future cash flows Revenue adjusted discount rate 28%
Schedule of Property and Equipment Estimated Useful Lives	Machinery and equipment 2-5 years Computer hardware and software 1-5 years LockeT animation video 3 years VIVO DEMO/Clinical Systems 1-5 years
Schedule of disaggregated product sales by geographic area	For the Three Months Ended September 30, For the Nine Months Ended September 30, 2024 2023 2024 2023 Product Sales US $ 62 $ 110 $ 129 $ 241 Europe 34 23 142 73 $ 96 $ 133 $ 271 $ 314

Business Combination (Tables)

Business Combination (Tables)	9 Months Ended
	Sep. 30, 2024
Business Combination
summary the preliminary estimated fair value	Description Fair Value as of January 9, 2023 Fair value of 14,649.592 Series X convertible preferred stock issued $ 69,140 Fair value of Old Catheter’s fully vested stock options 3,404 Total Purchase Price $ 72,544
summary Of preliminary purchase price allocations	Description Fair Value Assets acquired: Cash and cash equivalents $ 15 Accounts receivable 71 Inventories 52 Prepaid expenses and other current assets 23 Property and equipment, net 26 Lease right-of-use assets 119 Other assets 8 Developed technology 27,014 Customer relationships 62 Trademarks 1,285 Goodwill 60,934 Total assets acquired $ 89,609 Liabilities assumed: Accounts payable $ 922 Accrued expenses 1,389 Lease liability 124 Interest payable 198 Convertible promissory notes 250 Royalties payable 14,182 Total liabilities assumed 17,065 Total purchase price $ 72,544
Schedule of acquisition date fair values and estimated useful lives	Intangible Assets Fair Value Useful Life Developed technology- VIVO $ 8,244 15 Developed technology- LockeT 18,770 14 Customer relationships 62 6 Trademark- VIVO 876 9 Trademark- LockeT 409 9 $ 28,361 Three Months Ended September 30, Nine Months Ended September 30, 2023 2023 Revenues $ 133 $ 317 Net loss $ (1,927 ) $ (70,073 ) Net loss attributable to common stockholders $ (1,927 ) $ (70,873 ) Basic and diluted net loss per share – on a pro forma basis $ (0.28 ) $ (14.07 )

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2024
Inventories
Schedule of Inventories	September 30, 2024 December 31, 2023 Raw materials $ 4 $ 27 Finished goods 28 17 Inventories $ 32 $ 44

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Sep. 30, 2024
Property and Equipment
Schedule of Property and Equipment, Net	September 30, 2024 December 31, 2023 Machinery and equipment $ 29 $ 16 Computer hardware and software 29 17 LockeT Animation Video 29 — VIVO DEMO/Clinical Systems 101 69 Property and equipment, gross 188 102 Accumulated depreciation (77 ) (32 ) Property and equipment, net $ 111 $ 70

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2024
Intangible Assets
Schedule of Intangible Assets	Estimated Useful Life in Years Gross Carrying Amount at January 9, 2024 Accumulated Amortization Net Book Value at September 30, 2024 Developed technology ‐ VIVO 15 $ 8,244 $ (962 ) $ 7,282 Developed technology ‐ LockeT 14 18,770 (2,347 ) 16,423 Customer relationships 6 62 (18 ) 44 Trademarks/trade names ‐ VIVO 9 876 (170 ) 706 Trademarks/trade names ‐ LockeT 9 409 (79 ) 330 $ 28,361 $ (3,576 ) $ 24,785 Estimated Useful Life in Years Gross Carrying Amount at January 9, 2023 Accumulated Amortization Net Book Value at December 31, 2023 Developed technology ‐ VIVO 15 $ 8,244 $ (550 ) $ 7,694 Developed technology ‐ LockeT 14 18,770 (1,341 ) 17,429 Customer relationships 6 62 (10 ) 52 Trademarks/trade names ‐ VIVO 9 876 (97 ) 779 Trademarks/trade names ‐ LockeT 9 409 (45 ) 364 $ 28,361 $ (2,043 ) $ 26,318
Schedule of estimated future amortization expense	Years ending December 31, Future Amortization Expense Remainder of 2024 $ 510 2025 2,043 2026 2,043 2027 2,043 2028 2,043 Thereafter 16,103 Total $ 24,785

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2024
Accrued Expenses
Schedule of Accrued Expenses	September 30, 2024 December 31, 2023 Legal expenses $ 60 $ 102 Offering costs 1,356 1,356 Compensation and related benefits 33 43 Other accrued expenses 48 232 Accrued expenses $ 1,497 $ 1,733

Royalties Payable (Tables)

Royalties Payable (Tables)	9 Months Ended
	Sep. 30, 2024
Royalties Payable
summary of sales-based royalties	Royalty Percentage Until Royalty Payment Reaches a Total of 4% $ 1,589,500 2% $ 3,179,000 1% In perpetuity
summary of roll forward of the royalty payable	2024 2023 Beginning Balance, January 1, $ 6,974 $ — AMIGO royalty payable recognized in connection with the Merger — 159 LockeT royalty payable recognized in connection with the Merger — 14,022 Payments owed on royalties payable 17 — Change in fair value of royalties payable 2,823 (5,333 ) Ending Balance, September 30, $ 9,814 $ 8,848

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2024
Leases
Schedule of operating lease expense and cash paid for leases	For the Three Months Ended September 30, For the Nine Months Ended September 30, 2024 2023 2024 2023 Operating lease expense $ 28 $ 23 $ 80 $ 52 Cash paid for leases $ 25 $ 32 $ 78 $ 62
Schedule of weighted average discount rate	Weighted average remaining lease term (in years) - operating leases 1.37 Weighted average discount rate - operating leases 8.65 %
Schedule of Future lease payments for all lease	Years ending December 31: Operating Lease Remainder of 2024 $ 24 2025 98 2026 14 Total minimum lease payments 136 Less effects of discounting (1 ) Present value of future minimum lease payments $ 135
Schedule of Right of use lease assets and lease liabilities	September 30, December 31, 2024 2023 Assets Operating lease right-of-use assets, net $ 127 $ 179 Total lease assets $ 127 $ 179 Liabilities Current liabilities: Current portion of operating lease liabilities $ 99 $ 91 Non-current liabilities: Operating lease liabilities 36 97 Total lease liabilities $ 135 $ 188

Equity Offerings (Tables)

Equity Offerings (Tables)	9 Months Ended
	Sep. 30, 2024
Equity Offerings
Schedule of Black-Scholes Model Based on Assumptions	5/22/2020 Raise 8/3/2020 Raise Series B Series C Risk-free interest rate 4.06 % 4.06 % 3.60 % 3.66 % Volatility 135.35 % 132.55 % 115.42 % 127.65 % Expected dividend yield 0.00 % 0.00 % 0.00 % 0.00 % Expected life (in years) 2.4 2.6 6.5 4.5 Series F Series G Risk-free interest rate 3.8 % 3.4 % Volatility 80.0 % 74.0 % Expected dividend yield 0.0 % 0.0 % Expected life (in years) 2.0 6.0
Schedule of issuance of warrants	Number of shares Exercise Price Expiration 3,300 $312.50 5 years 3,100 $175.00 5 years
Schedule of Black-Scholes Model Based on Assumptions for placement fees	Value ($ in millions) Expected Volatility Risk-Free Interest Rate Expected Dividend Yield Expected Term (years) $0.4 93.25% 1.81% 0% 5.0 $0.2 96.70% 2.87% 0% 5.0
Schedule of common stock warrants outstanding	Warrants outstanding, December 31, 2023 1,104,217 Issued 13,724,435 Exercised (1,658,000 ) Expired — Warrants outstanding, September 30, 2024 13,170,652 Warrant Type Warrants Outstanding Exercise Price Expiration Date May 2020 Warrants 1,275 $ 5,625.00 5/20/2025 May 2020 Placement Agent Warrants 124 $ 7,031.25 5/20/2025 August 2020 Warrants 1,943 $ 4,375.00 8/3/2025 August 2020 Placement Agent Warrants 192 $ 5,468.75 7/30/2025 August 2021 Pharos Banker Warrants 148 $ 1,495.00 8/16/2026 February 2022 Series B Warrants 39,153 $ 140.00 2/4/2029 July 2022 Series C Warrants 28,404 $ 140.00 7/22/2027 January 2023 Series E Warrants 33,161 $ 40.00 3/21/2028 March 2023 Series F Warrants 499,909 $ 30.00 3/21/2025 March 2023 Series G Warrants 499,909 $ 30.00 3/21/2029 September 2024 Pre-Funded Warrants 1,115,000 $ 0.00 None September 2024 Series H Warrants 3,578,900 $ 1.00 3/3/2025 September 2024 Series I Warrants 3,578,900 $ 1.00 3/3/2026 September 2024 Series J Warrants 3,578,900 $ 1.00 9/3/2029 September 2024 Representative Warrants 214,734 $ 1.55 8/29/2029 13,170,652

Preferred Stock (Tables)

Preferred Stock (Tables)	9 Months Ended
	Sep. 30, 2024
Preferred Stock
Schedule of Series A Convertible Preferred Stock occurred subsequent to the issuance	Date of Conversion Series A Shares Converted Common Shares Issued July 5, 2023 1,750 109,355 July 24, 2023 875 54,678 January 24, 2024 875 54,678 July 1, 2024 1,303 81,423 July 11, 2024 1,000 62,489 July 22, 2024 1,000 62,500 July 23, 2024 400 25,000

StockBased Compensation (Tables

StockBased Compensation (Tables)	9 Months Ended
	Sep. 30, 2024
StockBased Compensation
Schedule of Options Activity	Non-Employee Director Options Issued January 8, 2024 Employee Options Issued January 8, 2024 Employee Options Issued February 26, 2024 Employee Options Issued April 24, 2024 Employee Options Issued July 9, 2024 Risk-free interest rate 4.01 % 4.01 % 4.28 % 4.65 % 4.30 % Volatility 175.36 % 175.36 % 178.14 % 211.61 % 214.61 % Expected dividend yield 0 % 0 % 0 % 0 % 0 % Expected life (in years) 6.5 6.5 6.5 6.5 6.5 Non-Plan Options Issued May 1, 2024 Risk-free interest rate 4.63 % Volatility 211.61 % Expected dividend yield 0 % Expected life (in years) 6.5
Schedule of Unrecognized Estimated Stock Based Compensation Expense by Award Type	Stock Options Weighted Average Exercise Price Weighted Average Remaining Life (in years) Aggregate Intrinsic Value (in thousands) Outstanding at December 31, 2023 21,465 $ 64.71 6.38 $ — Options exercised — $ — — — Options granted 91,000 $ 4.42 — — Cancelled/forfeited (16,652 ) $ 4.50 — — Outstanding at September 30, 2024 95,813 $ 17.92 8.86 $ 4,510.00 Vested and expected to vest at September 30, 2024 95,813 $ 17.92 8.86 $ 4,510.00 Exercisable at September 30, 2024 18,148 $ 75.35 6.07 $ — Unrecognized Expense (in thousands) Remaining Weighted Average Recognition Period (in years) Stock options $ 309 4.4 Restricted stock awards $ — — Restricted stock units $ — —

Related Parties (Tables)

Related Parties (Tables)	9 Months Ended
	Sep. 30, 2024
Related Parties
Schedule of Related parties and the amounts owed to each related party	Related Party Issuance Date Principal Amount Interest Paid Interest Accrued David Jenkins 5/30/2024 $ 500 $ 10 $ 5 FatBoy Capital 6/25/2024 $ 150 $ 2 $ 2 FatBoy Capital 7/1/2024 $ 250 $ 3 $ 3 FatBoy Capital 7/18/2024 $ 100 $ 1 $ 1 Jenkins Family Charitable Institute 7/25/2024 $ 500 $ 4 $ 5

Subsequent Events (Tables)

Subsequent Events (Tables)	9 Months Ended
	Sep. 30, 2024
Subsequent Events
Schedule of Issuance of Securities from Warrant Exercises	Name of Warrant Exercise Date Issue Date Shares Common Stock Issued Number of Warrants Exercised Proceeds September 2024 Pre-Funded Warrant 10/3/2024 10/4/2024 250,000 250,000 $ — September 2024 Pre-Funded Warrant 10/16/2024 10/16/2024 196,000 196,000 $ — September 2024 Pre-Funded Warrant 10/18/2024 10/21/2024 434,000 434,000 $ — September 2024 Series H Warrant 10/18/2024 10/21/2024 1,010,000 1,010,000 $ 1,010 September 2024 Series I Warrant 10/18/2024 10/21/2024 175,000 175,000 $ 175 September 2024 Pre-Funded Warrant 10/29/2024 10/29/2024 235,000 235,000 $ —

Organization and Nature of Op_2

Organization and Nature of Operations (Details Narrative) - USD ($) $ / shares in Units, $ in Millions		9 Months Ended
	Jul. 15, 2024	Sep. 30, 2024	Dec. 31, 2023
Cash flows used in operating activities		$ 6.4
Common Stock, shares authorized		30,000,000	300,000,000
Common stock, Par value		$ 0.0001	$ 0.0001
Cash and cash equivalents		$ 1.3
Accumulated deficit		(287)
Reverse Stock Split [Member]
Common Stock, shares authorized	30,000,000
Common stock, Par value	$ 0.0001
Effected reverse stock split shares	10
Non assessable share of common stock, per share	$ 0.0001
Related Party Notes [Member]
Short-term promissory notes		$ 1.5
Interest Rate		8%
September 2024 Public Offering [Member]
Common Stock Units		805,900
Pre-Funded Units		2,773,000
Gross proceeds		$ 3.6
Equity Offerings Costs		$ 1
2024 Inducement Offer [Member]
Description of warrant inducement		such warrant holders immediately exercised up to an aggregate of (i) 33,160.8 Series E Warrants, (ii) 499,909.34 Series F Warrants, (iii) 499,909.34 Series G Warrants, (iv) 1,990,000 Series H Warrants, and (v) 2,325,000 Series I Warrants (collectively the “Existing Warrants”) to purchase up to approximately 5.3 million shares of the Company’s Common Stock at a reduced exercise price of $0.70 per share. In consideration for the immediate exercise of the Existing Warrants for cash, the Company agreed to issue unregistered new Series K Common Stock Purchase Warrants (“Series K Warrants”) to purchase up to 10.7 million shares of common stock. The Company expects to receive aggregate gross proceeds of approximately $3.7 million in cash from the exercise of these warrants pursuant to the 2024 Inducement Offer, prior to deducting placement agent fees and offering expense of $0.4 million. As of the date of the 2024 Inducement Offer, 578,900 Series H and 1,078,900 Series I warrants remained unexercised. As additional consideration, the Company issued placement agent warrants to purchase up to 320,879 shares of common stock on the same terms as the Series K warrants, except the exercise price is $1.085 per share and have a termination date of October 28, 2029

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Mutual fund	$ 1,237	$ 3,397
Money market fund	18	10
Total assets	1,255	3,407
Royalties payable	9,797	6,974
Total liabilities	9,797	6,974
Level 1 [Member]
Mutual fund	1,237	3,397
Money market fund	18	10
Total assets	1,255	3,407
Royalties payable	0	0
Total liabilities	0	0
Level 2 [Member]
Mutual fund	0	0
Money market fund	0	0
Total assets	0	0
Royalties payable	0	0
Total liabilities	0	0
Level 3 [Member]
Mutual fund		0
Money market fund	0	0
Total assets	0	0
Royalties payable	9,797	6,974
Total liabilities	$ 9,797	$ 6,974

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details 1)	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Summary of Significant Accounting Policies
Valuation Technique	Discounted future cash flows	Discounted future cash flows
Unobservable Input	Revenue adjusted discount rate	Revenue adjusted discount rate
Input Range	20%	28%

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details 2)	9 Months Ended
	Sep. 30, 2024
Computer Hardware And Software [Member] | Minimum [Member]
Estimated useful lives	1 year
Computer Hardware And Software [Member] | Maximum [Member]
Estimated useful lives	5 years
VIVO DEMO/Clinical Systems[Member] | Minimum [Member]
Estimated useful lives	1 year
VIVO DEMO/Clinical Systems[Member] | Maximum [Member]
Estimated useful lives	5 years
Locket Animation Video [Member]
Estimated useful lives	3 years
Machinery And Equipment [Member] | Minimum [Member]
Estimated useful lives	2 years
Machinery And Equipment [Member] | Maximum [Member]
Estimated useful lives	5 years

Summary of Significant Accoun_7

Summary of Significant Accounting Policies (Details 3) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenue by location	$ 96	$ 133	$ 271	$ 314
Europe [Member]
Revenue by location	34	23	142	73
US [Member]
Revenue by location	$ 62	$ 110	$ 129	$ 241

Summary of Significant Accoun_8

Summary of Significant Accounting Policies (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Impairment charges				$ 60,900
Deemed dividend amount for existing warrants and issuance of new warrants		$ 0		800
Description of legal limit			The Company maintains deposits in financial institutions in excess of federally insured limits of $250,000, in the amount of $987 thousand
Royalty liability description			The Company will pay to the Noteholders a royalty equal to 11.82% of net sales of LockeT, commencing on the first commercial sale through December 31, 2035
Royalty rate			11.82%
Advertising and marketing	$ 31	$ 309	$ 127	$ 914
Revenue Member | Three and Five Customers Member
Concentration risk	90%		86%
Revenue Member | Three and Four Customers [Member]
Concentration risk		71%		73%

Business Combination (Details)

Business Combination (Details) $ in Thousands	Jan. 09, 2023 USD ($)
Total Purchase Price	$ 72,544
Catheter's [Member]
fair value of options issued	3,404
Convertible Series X Preferred Stock [Member]
fair value of convertible preferred stock issued	$ 69,140

Business Combination (Details 1

Business Combination (Details 1) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Jan. 09, 2023
Accounts payable	$ 708	$ 464
Accrued expenses	1,497	1,733
Lease liability	99	91
Interest payable	16	0
Convertible promissory note						$ 25,100
Royalties payable	9,797	6,974
Cash and cash equivalents	1,268	3,565
Inventories	32	44
Prepaid expenses and other current assets	307	415
Property and equipment, net	111	70
Lease right of use assets	127	179
Other assets	$ 1,255	$ 3,407
Goodwill			$ 60,900	$ 60,900	$ 56,000
Liabilities assumed [Member]
Accounts payable						922
Accrued expenses						1,389
Lease liability						124
Interest payable						198
Convertible promissory note						250
Royalties payable						14,182
Total liabilities assumed						17,065
Total purchase price						72,544
Assets Acquired [Member]
Cash and cash equivalents						15
Accounts receivable						71
Inventories						52
Prepaid expenses and other current assets						23
Property and equipment, net						26
Lease right of use assets						119
Other assets						8
Developed technology						27,014
Customer relationships						62
Trademarks						1,285
Goodwill						60,934
Total assets acquired						$ 89,609

Business Combination (Details 2

Business Combination (Details 2) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Jan. 09, 2023
Intangible assets acquired		$ 28,361
Customer Relationships [Member]
Intangible assets acquired		62
Estimated Useful Life	6 years
Developed Technology - VIVO [Member]
Intangible assets acquired		8,244
Estimated Useful Life	15 years
Developed technology- LockeT [Member]
Intangible assets acquired		18,770
Estimated Useful Life	14 years
Trademark- VIVO [Member]
Intangible assets acquired		876
Estimated Useful Life	9 years
Trademark- LockeT [Member]
Intangible assets acquired		$ 409
Estimated Useful Life	9 years

Business Combination (Details 3

Business Combination (Details 3) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenues	$ 96			$ 133			$ 271	$ 314
Net loss	$ (4,120)	$ (4,220)	$ (2,675)	(1,927)	$ (1,576)	$ (66,400)	$ (11,015)	(69,903)
Pro Forma Financial Information [Member]
Revenues				133				317
Net loss				(1,927)				(70,073)
Net loss attributable to common stockholders				$ (1,927)				$ (70,873)
Basic and diluted net loss per share - on a pro forma basis				$ (0.28)				$ (14.07)

Business Combination (Details N

Business Combination (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended	9 Months Ended
	Jan. 09, 2023	Sep. 30, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023
Merger Agreement [Member]
Developed technologies assets				$ 27,000	$ 35,100
Trademarks				1,300	1,700
Customer relationships				62	220
Goodwill				60,900	56,000
Royalties payable				$ 14,200	$ 7,600
Total Impairment charge			$ 60,900
Transaction costs for the merger		$ 0	$ 1,700
Merger Agreement One [Member]
Convertible promissory note	$ 25,200
Series X preferred stock shares	14,649
Purchase shares of common stock	75,367
Total purchase consideration	$ 72,500
Estimated fair value of the Convertible Preferred Stock issued	14,649
Value of stock option issued	$ 3,400
Closing stock price	$ 60.90

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Inventories
Raw materials	$ 4	$ 27
Finished goods	28	17
Inventories	$ 32	$ 44

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Property and equipment, gross	$ 188	$ 102
Accumulated depreciation	(77)	(32)
Property and equipment, net	111	70
Locket Animation Video [Member]
Property and equipment, gross	29	0
Computer Hardware And Software [Member]
Property and equipment, gross	29	17
VIVO DEMO/Clinical Systems[Member]
Property and equipment, gross	101	69
Machinery And Equipment [Member]
Property and equipment, gross	$ 29	$ 16

Property and Equipment (Detai_2

Property and Equipment (Details narrative) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Property and Equipment
Depreciation expense	$ 19	$ 9	$ 45	$ 26

Intangible Assets (Details)

Intangible Assets (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2024	Dec. 31, 2023	Jan. 09, 2024	Jan. 09, 2023
Gross Carrying Amount			$ 28,361	$ 28,361
Accumulated Amortization		$ (2,043)		(3,576)
Net Book Value	$ 24,785	26,318		24,785
Customer Relationships [Member]
Gross Carrying Amount			62	62
Accumulated Amortization	(18)	(10)
Net Book Value	$ 44	$ 52
Estimated Useful Life in Years	6 years	6 years
Trademarks/trade Names - VIVO [Member]
Gross Carrying Amount			876	876
Accumulated Amortization	$ (170)	$ (97)
Net Book Value	$ 706	$ 779
Estimated Useful Life in Years	9 years	9 years
Trademarks/trade Names - LockeT [Member]
Gross Carrying Amount			409	409
Accumulated Amortization	$ (79)	$ (45)
Net Book Value	$ 330	$ 364
Estimated Useful Life in Years	9 years	9 years
Developed Technology - VIVO [Member]
Gross Carrying Amount			8,244	8,244
Accumulated Amortization	$ (962)	$ (550)
Net Book Value	$ 7,282	$ 7,694
Estimated Useful Life in Years	15 years	15 years
Developed technology- LockeT [Member]
Gross Carrying Amount			$ 18,770	$ 18,770
Accumulated Amortization	$ (2,347)	$ (1,341)
Net Book Value	$ 16,423	$ 17,429
Estimated Useful Life in Years	14 years	14 years

Intangible Assets (Details 1)

Intangible Assets (Details 1) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023	Jan. 09, 2023
Intangible Assets
Remainder of 2024	$ 510
2025	2,043
2026	2,043
2027	2,043
2028	2,043
Thereafter	16,103
Total	$ 24,785	$ 26,318	$ 24,785

Intangible Assets (Details narr

Intangible Assets (Details narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Intangible Assets
Amortization expense	$ 500,000	$ 500,000	$ 1,500,000	$ 1,500,000
Weighted average remaining amortization period			12 years 3 months 25 days

Goodwill (Details Narrative)

Goodwill (Details Narrative) - USD ($) $ in Millions	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023
Goodwill
Goodwill		$ 60.9	$ 60.9	$ 56
Cumulative goodwill impairment charges	$ 60.9

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Accrued Expenses
Legal expenses	$ 60	$ 102
Offering costs	1,356	1,356
Compensation and related benefits	33	43
Other accrued expenses	48	232
Accrued expenses	$ 1,497	$ 1,733

Accrued Expenses (Details Narra

Accrued Expenses (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Sep. 30, 2024
Accrued Expenses
Removal of accrued warranty	$ 192
Accrued warranty balance		$ 0

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	1 Months Ended					3 Months Ended		9 Months Ended
	Sep. 26, 2024	Jul. 18, 2024	Jun. 25, 2024	May 30, 2024	Oct. 16, 2023	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Jul. 02, 2024	Jun. 30, 2024	Dec. 31, 2023
Interest expenses						$ 32,000	$ 0	$ 40,000	$ 18,000
Loan to company			$ 150,000
Notes payable						249,000		249,000				$ 184,000
Short Term Promissory Notes [Member]
Interest expenses						33,000		36,000
Interest payable to related parties						16,000		$ 16,000
Loan to company			$ 500,000
Maturity date of related party notes								August 30, 2024
Interest rate of related party			12%					8%
Interest payable											$ 4,000
Notes Payable and accrued interest	$ 21,000					1,500,000		$ 1,500,000
Short Term Promissory Notes [Member] | David A Jenkin [Member]
Loan to company		$ 100,000		$ 500,000
Short Term Promissory Notes [Member] | Mr. Jenkins [Member]
Short term loan										$ 250,000
Notes Payable Director And Officer [Member]
Note payable to third party					$ 291,000	249,000		249,000
Short-term financing								249,000
Down payment against purchase of director and officer liability insurance coverage	44,000				157,000
Purchase of director and officer liability insurance coverage	$ 293,000				$ 447,000
Interest expenses						1,000
Interest expense on loan						$ 0		$ 0
Interest rate of loan	9.99%				8.99%
Notes payable												$ 184,000

Royalties Payable (Details)

Royalties Payable (Details)	9 Months Ended
	Sep. 30, 2024 USD ($)
Royalty Payment	$ 10,000,000
Royalty Two [Member]
Royalty Percentage	2%
Royalty Payment	$ 3,179,000
Royalty One [Member]
Royalty Percentage	4%
Royalty Payment	$ 1,589,500
Royalty Three [Member]
Royalty Percentage	1%
Royalty Payment	In perpetuity

Royalties Payable (Details 1)

Royalties Payable (Details 1) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Royalties Payable
Balance at beginning of period	$ 6,974	$ 0
AMIGO royalty payable recognized in connection with the Merger	0	159
LockeT royalty payable recognized in connection with the Merger	0	14,022
Payments owed on royalties payable	17	0
Change in fair value of royalties payable	2,823	(5,333)
Balance at end of period	$ 9,814	$ 8,848

Royalties Payable (Details Narr

Royalties Payable (Details Narrative) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Dec. 31, 2023
Royalties payable	$ 9,797	$ 6,974
Payments for Royalties	10,000
Termination payments for Royalties	$ 10,000
Royalty payments description	The royalty payments will apply to revenues through December 31, 2033
Royalty of net sales	2%
LockeT Royalty [Member]
Royalty payable, Percentage	12%
Royalties payable	$ 17
Description of lockeT device inventor	the inventor of the LockeT device as detailed in the Royalty Agreement. In exchange for the assignment and all rights to LockeT, the Company will pay a 5% royalty on net sales up to $1.0 million in royalties
AMIGO System Royalty [Member]
Investment amount received	$ 1,600

Leases (Details)

Leases (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Leases
Operating lease expense	$ 28	$ 23	$ 80	$ 52
Cash paid for leases	$ 25	$ 32	$ 78	$ 62

Leases (Details 1)

Leases (Details 1)	9 Months Ended
	Sep. 30, 2024
Leases
Weighted average discount rate - operating leases	8.65%
Weighted average remaining lease term (in years) - operating leases	1 year 4 months 13 days

Leases (Details 2)

Leases (Details 2) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Leases
Remainder of 2024	$ 24
2025	98
2026	14
Total minimum lease payments	136
Less effects of discounting	(1)
Present value of future minimum lease payments	$ 135	$ 188

Leases (Details 3)

Leases (Details 3) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Leases
Lease right-of-use assets	$ 127	$ 179
Total lease assets	127	179
Lease liability - current portion	99	91
Lease liability - net of current portion	36	97
Total lease liabilities	$ 135	$ 188

Leases (Details Narrative)

Leases (Details Narrative)	9 Months Ended
	Sep. 30, 2024 USD ($)
South Carolina Office Lease Agreement [Member]
Total rent expense per month	$ 3,435
Lease agreement term	36 years
New Jersey Office Lease Agreement [Member]
Total rent expense per month	$ 1,207
Rent expense for extended period per month	$ 1,267
Lease agreement term	24 years
Lease agreement term extended period	12 years
Park City Office Lease Agreement [Member]
Total rent expense per month	$ 3,200
Lease agreement term	36 years

Net Loss per Share (Details Nar

Net Loss per Share (Details Narrative) - USD ($) $ in Millions				1 Months Ended				3 Months Ended	9 Months Ended
	Jul. 11, 2024	Jul. 02, 2024	Jul. 05, 2023	Jul. 23, 2024	Jul. 22, 2024	Jan. 24, 2024	Jul. 24, 2023	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Deemed dividend amount								$ 0		$ 0.8
Series A convertible preferred stock [Member]
Convertible preferred stock	1,000	1,303	1,750	400	1,000	875	875			286,125
Series x convertible preferred stocks [Member]
Convertible preferred stock									1,265,601	1,267,469
Stock Options [Member]
Anti-dilutive common share equivalents excluded from computation of diluted net loss per share									95,813	21,465
Warrants [Member]
Anti-dilutive common share equivalents excluded from computation of diluted net loss per share									13,170,652	1,104,215
Restricted Stock Units [Member]
Anti-dilutive common share equivalents excluded from computation of diluted net loss per share										2

Equity Offerings (Details)

Equity Offerings (Details) - 2023 Warrant Repricing [Member]	Jan. 09, 2023
Series B Warrants [Member]
Risk-free interest rate	3.60%
Volatility	115.42%
Expected dividend yield	0%
Expected life (in years)	6 years 6 months
Series C Warrants [Member]
Risk-free interest rate	3.66%
Volatility	127.65%
Expected dividend yield	0%
Expected life (in years)	4 years 6 months
Series E Warrants [Member]
Risk-free interest rate	3.66%
Volatility	124.07%
Expected dividend yield	0%
Expected life (in years)	5 years
5/22/2020 Raise [Member]
Risk-free interest rate	4.06%
Volatility	135.35%
Expected dividend yield	0%
Expected life (in years)	2 years 4 months 24 days
8/3/20 Raise [Member]
Risk-free interest rate	4.06%
Volatility	132.55%
Expected dividend yield	0%
Expected life (in years)	2 years 7 months 6 days

Equity Offerings (Details 1)

Equity Offerings (Details 1) - Private Placement [Member]	Jan. 09, 2023
Series F Warrants [Member]
Risk-free interest rate	3.80%
Volatility	80%
Expected dividend yield	0%
Expected life (in years)	2 years
Series G Warrants [Member]
Risk-free interest rate	3.40%
Volatility	74%
Expected dividend yield	0%
Expected life (in years)	6 years

Equity Offerings (Details 2)

Equity Offerings (Details 2) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2022	Sep. 30, 2024
Warrants outstanding		13,170,652
2022 Offering [Member] | Warrant One [Member]
Warrants outstanding	3,300
Exercise Price	$ 312.50
Expiration Date	5.0
Warrants outstanding, value	$ 0.4
Risk-free interest rate	1.81%
Volatility	93.25%
Expected dividend yield	0%
Expected life (in years)	5 years
2022 Offering [Member] | Warrant Two [Member]
Warrants outstanding	3,100
Exercise Price	$ 175
Expiration Date	5.0
Warrants outstanding, value	$ 0.2
Risk-free interest rate	2.87%
Volatility	96.70%
Expected dividend yield	0%
Expected life (in years)	5 years

Equity Offerings (Details 3)

Equity Offerings (Details 3)	9 Months Ended
	Sep. 30, 2024 shares
Warrants outstanding, Ending balance	13,170,652
Warrants [Member]
Warrants outstanding, Beginning balance	1,104,217
Issued	13,724,435
Exercised	(1,658,000)
Expired	0
Warrants outstanding, Ending balance	13,170,652

Equity Offerings (Details 4)

Equity Offerings (Details 4)	9 Months Ended
	Sep. 30, 2024 $ / shares shares
Warrants outstanding	13,170,652
Pre-Funded Warrants
Warrants outstanding	1,115,000
Exercise Price | $ / shares	$ 0
Expiration Date	0
Series H Warrants [Member]
Warrants outstanding	3,578,900
Exercise Price | $ / shares	$ 1
Expiration Date	3/3/2025
Series I Warrants [Member]
Warrants outstanding	3,578,900
Exercise Price | $ / shares	$ 1
Expiration Date	3/3/2026
Series J Warrants [Member]
Warrants outstanding	3,578,900
Exercise Price | $ / shares	$ 1
Expiration Date	9/3/2029
May 2020 Warrants
Warrants outstanding	1,275
Exercise Price | $ / shares	$ 5,625
Expiration Date	5/20/2025
May 2020 Placement Agent Warrants
Warrants outstanding	124
Exercise Price | $ / shares	$ 7,031.25
Expiration Date	5/20/2025
August 2020 Warrants
Warrants outstanding	1,943
Exercise Price | $ / shares	$ 4,375
Expiration Date	8/3/2025
August 2020 Placement Agent Warrants
Warrants outstanding	192
Exercise Price | $ / shares	$ 5,468.75
Expiration Date	7/30/2025
August 2021 Pharos Banker Warrants
Warrants outstanding	148
Exercise Price | $ / shares	$ 1,495
Expiration Date	8/16/2026
February 2022 Series B Warrants
Warrants outstanding	39,153
Exercise Price | $ / shares	$ 140
Expiration Date	2/4/2029
July 2022 Series C Warrants
Warrants outstanding	28,404
Exercise Price | $ / shares	$ 140
Expiration Date	7/22/2027
January 2023 Series E Warrants
Warrants outstanding	33,161
Exercise Price | $ / shares	$ 40
Expiration Date	3/21/2028
March 2023 Series F Warrants
Warrants outstanding	499,909
Exercise Price | $ / shares	$ 30
Expiration Date	3/21/2025
March 2023 Series G Warrants
Warrants outstanding	499,909
Exercise Price | $ / shares	$ 30
Expiration Date	3/21/2029
Representative Warrants [Member]
Warrants outstanding	214,734
Exercise Price | $ / shares	$ 1.55
Expiration Date	8/29/2029

Equity Offerings (Details Narra

Equity Offerings (Details Narrative) - USD ($)						1 Months Ended				3 Months Ended	9 Months Ended
	Sep. 03, 2024	Jul. 11, 2024	Jul. 02, 2024	Jul. 05, 2023	Jan. 09, 2023	Jul. 23, 2024	Jul. 22, 2024	Jan. 24, 2024	Jul. 24, 2023	Sep. 30, 2023	Sep. 30, 2023	Sep. 30, 2024	Aug. 30, 2024	Dec. 31, 2023
Warrants exercise price	$ 0.0001
Common stock, weighted average exercise price					$ 3
Accrued expenses												$ 1,497,000		$ 1,733,000
Incremental fair value of the repriced warrants					$ 300,000
Aggregate purchase price					8,000,000
Fair value of Series E warrant					1,900,000
Weighted average exercise price												$ 5.29
Deemed dividend amount										$ 0	$ 800,000
Series E Warrants [Member]
Repriced warrants					$ 1,900,000
2022 Offering [Member]
Accrued expenses												$ 1,400,000
Common Stocks | At The Market Offerings.
Warrants exercise price					$ 40
Stock Issued During Period Shares New Issues					33,161
Net proceeds					$ 1,100,000
Series A Warrants [Member]
Proceeds From Issuance Of Common Stock					900,000
Payments Of Stock Issuance Costs					$ 1,000
Percentage of shares exercised					9.99%
Percentage of shares exercised beneficially					4.99%
Series B Warrants [Member]
Warrants exercise price					$ 30
Proceeds From Issuance Of Common Stock					$ 7,100,000
Payments Of Stock Issuance Costs					$ 1,000
Class B preferred stock issued and converted to Series A preferred stock					7,203
Series A convertible preferred stock [Member]
Class B preferred stock issued and converted to Series A preferred stock		1,000	1,303	1,750		400	1,000	875	875		286,125
Series F and Series G Warrants. | Private Placement [Member]
Warrants exercise price					$ 30
Valuation of warrants					$ 5,500,000
Percentage of shares exercised					9.99%
Percentage of shares exercised beneficially					4.99%
Series H Warrant, Series I Warrant, Series J Warrant | 2024 Public Offering [Member]
Warrants exercise price	$ 1.55
Stock Issued During Period Shares New Issues	805,900
Public offering price	$ 1
Underwriting discounts and commissions	1.0
Pre-Funded Warrant Units	$ 0.9999
Pre-Funded Warrant Units Issued	2,773,000
Percentage of shares exercised	9.99%
Percentage of shares exercised beneficially	4.99%
Gross proceeds	$ 3,600,000
Net proceeds from public offering	$ 2,600,000
Issuance of warrants	214,734
Warrant Repricing [Member]
Warrants exercise price					$ 40
Proceeds From Issuance Of Common Stock					$ 1,300,000
Fee withheld					$ 200,000
Stock issued during period, warrants exercised					33,161
Series H Warrants [Member]
Warrants exercise price	$ 1
Series I Warrants [Member]
Warrants exercise price	1
Series J Warrants [Member]
Warrants exercise price	$ 1
Underwriting Agreement [Member]
Option to purchase additional shares of Common Stock												468,041	458,623
Common Stock Units												805,900	458,623
Underwriting Agreement [Member] | Series H Warrants [Member]
Option to purchase additional shares of Common Stock												468,041	458,623
Underwriting Agreement [Member] | Series I Warrants [Member]
Option to purchase additional shares of Common Stock												468,041	458,623
Underwriting Agreement [Member] | Series J Warrants [Member]
Option to purchase additional shares of Common Stock												468,041	458,623
Securities Purchase AgreeMent [Member] | Series A convertible preferred stock [Member] | Private Placement [Member]
Stock Issued During Period Shares New Issues					497,908
Securities Purchase AgreeMent Class B [Member] | Series A convertible preferred stock [Member] | Private Placement [Member]
Stock Issued During Period Shares New Issues					450,123
Minimum [Member] | Existing warrants.
Warrants exercise price					$ 140
Maximum [Member] | Existing warrants.
Warrants exercise price					$ 5,265

Preferred Stock (Details)

Preferred Stock (Details) - Series A convertible preferred stock [Member] - shares				1 Months Ended				9 Months Ended
	Jul. 11, 2024	Jul. 02, 2024	Jul. 05, 2023	Jul. 23, 2024	Jul. 22, 2024	Jan. 24, 2024	Jul. 24, 2023	Sep. 30, 2023
Common Shares Issued	62,489	81,423	109,355	25,000	62,500	54,678	54,678
Class B preferred stock issued and converted to Series A preferred stock	1,000	1,303	1,750	400	1,000	875	875	286,125

Preferred Stock (Details Narrat

Preferred Stock (Details Narrative) - USD ($) $ / shares in Units, $ in Millions		9 Months Ended
	Jan. 09, 2023	Sep. 30, 2024	Dec. 31, 2023	Oct. 24, 2023	Mar. 23, 2023	Mar. 21, 2023
Common stock share issued		3,452,652	702,662
Conversion of preferred stock	7,856
Series X convertible preferred stocks [Member]
Convertible promissory notes, representing an aggregate principal	$ 25.2
Description of convertible Preferred Stock	were converted into a right to receive 14,649.592 shares of a new class of the Company’s preferred stock, designated Series X Convertible Preferred Stock
Principal amount per share	$ 32
Initial rate of share listing price		$ 100
Common stock share issued				1,868	197,491	199,359
Conversion of preferred stock				18	1,974	1,993
Common stock Convertible Preferred Stock description		The remaining 12,656.011 shares of Series X Convertible Preferred Stock are expected to remain outstanding until the Company meets the initial listing standards of the NYSE American or another national securities exchange or is delisted from the NYSE American, at which time they will convert into common stock
Series A convertible preferred stock [Member]
Description of private investment in public equity	Series A Convertible Preferred Stock will not have the right to convert any portion of their Series A Convertible Preferred Stock if the holder, together with its affiliates, would beneficially own in excess of 9.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to its conversion

StockBased Compensation (Detail

StockBased Compensation (Details)			1 Months Ended
	Jul. 09, 2024	Jan. 08, 2024	Apr. 24, 2024	Feb. 26, 2024
Employees [Member]
Risk-free interest rate	4.30%	4.01%	4.65%	4.28%
Volatility	214.61%	175.36%	211.61%	178.14%
Expected dividend yield	0%	0%	0%	0%
Expected life (in years)	6 years 6 months	6 years 6 months	6 years 6 months	6 years 6 months
Non-Employee Director Options Issued [Member]
Risk-free interest rate		4.01%
Volatility		175.36%
Expected dividend yield		0%
Expected life (in years)		6 years 6 months

StockBased Compensation (Deta_2

StockBased Compensation (Details 1) - Non-Plan Options Issued [Member] - May 1, 2024 [Member]	9 Months Ended
	Sep. 30, 2024
Risk-free interest rate	4.63%
Volatility	211.61%
Expected dividend yield	0%
Expected life (in years)	6 years 6 months

StockBased Compensation (Deta_3

StockBased Compensation (Details 2) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($) $ / shares shares
StockBased Compensation
Stock option outstanding beginning of the period | shares	21,465
Stock option options exercised | shares	0
Stock option options granted | shares	91,000
Stock option canceled/forfeited | shares	(16,652)
Stock option outstanding end of the period | shares	95,813
Vested and expected to vest at September 30, 2024 | shares	95,813
Exercisable at September 30, 2024 | shares	18,148
Weighted average exercised price outstanding beg of period | $ / shares	$ 64.71
Weighted average exercised price Options exercised | $ / shares	0
Weighted average exercised price options granted | $ / shares	4.42
Weighted average exercised price canceled/forfeited | $ / shares	4.50
Weighted average exercised price outstanding end of period | $ / shares	17.92
Weighted average exercised price vested and expected to vest end of the period | $ / shares	17.92
Weighted average exercised price exercisable at September 30, 2024 | $ / shares	$ 75.35
Weighted Average Remaining Life end of period exercisable, begin	6 years 4 months 17 days
Weighted Average Remaining Life end of period exercisable, end	8 years 10 months 9 days
Weighted Average Remaining Life Vested and expected to vest end of period	8 years 10 months 9 days
Weighted Average Remaining Life end of period	6 years 25 days
Aggregate Intrinsic Value outstanding ending balance | $	$ 4,510
Aggregate Intrinsic Value outstanding beginning balance | $	0
Aggregate Intrinsic Value, Vested and expected to vest at September 30, 2024 | $	4,510
Aggregate Intrinsic Value, Exercisable at September 30, 2024 | $	$ 0

StockBased Compensation (Deta_4

StockBased Compensation (Details 3) $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($)
Stock options [Member]
Remaining Weighted Average Recognition Period	4 years 4 months 24 days
Total unrecognized estimated stock-based compensation expense	$ 309
Restricted Stock Units [Member]
Remaining Weighted Average Recognition Period	0 years
Total unrecognized estimated stock-based compensation expense	$ 0
Restricted Stock Awards [Member]
Remaining Weighted Average Recognition Period	0 years
Total unrecognized estimated stock-based compensation expense	$ 0

StockBased Compensation (Deta_5

StockBased Compensation (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

Jul. 09, 2024

Jan. 08, 2024

Jan. 09, 2023

Apr. 24, 2024

Feb. 26, 2024

Sep. 30, 2018

Sep. 30, 2024

Sep. 30, 2023

Sep. 30, 2024

Sep. 30, 2023

Dec. 31, 2023

Sep. 03, 2024

Exercise price

$ 0.0001

2018 Equity Stock Purchase Plan [Member]

Shares issued under employee stock purchase plan

95

95

Percentage of fair market value of share of common stock to purchase

85%

Eligible employees withhold percentage of earnings to purchase shares of common stock

15%

Maximum annual increase of outstanding stock reserved for future issuance, Percentage

1.25%

Common stock reserve for issuance

23

23

2

2020 Stock Option Plan [Member]

Common stock reserve for issuance

0

0

54

2020 Stock Option Plan [Member] | Restricted Stock Awards [Member]

Common stock reserve for issuance

64

2018 Stock Compensation Plan [Member]

Stock-based compensation

$ 17

$ 2

$ 36

$ 1,200

2023 Stock Option Plan [Member]

Maximum annual increase of outstanding stock reserved for future issuance, Percentage

10%

Common stock reserve for issuance

225,085

225,085

50,186

2023 Equity Incentive Plan [Member]

Equity Incentive Plan description

vest at 20% per year for 5 years with an exercise price of $3.50 and expiration date of July 9, 2034

vest at 20% per year for 5 years with an exercise price of $4.60 and expiration date of April 24, 2034

Value of options issued

$ 262

Issuance of options

10,000

28,500

12,500

Exercise price

$ 3.50

$ 4.60

2023 Equity Incentive Plan [Member] | Director [Member]

Equity Incentive Plan description

vest at 8 1/3% per quarter for 3 years with an exercise price of $4.00 and expiration date of January 8, 2034

Issuances of options

7,500

Exercise price

$ 4

2023 Equity Incentive Plan [Member] | Employees And Consultants [Member]

Equity Incentive Plan description

vest at 20% per year for 5 years with an exercise price of $4.00 and expiration date of January 8, 2034

Issuances of options

21,000

Exercise price

$ 4

2023 Equity Incentive Plan [Member] | Employees [Member]

Equity Incentive Plan description

vest at 20% per year for 5 years with an exercise price of $4.20 and expiration date of February 26, 2034

Issuance of options

15,000

Exercise price

$ 4.20

Non-Plan Options Issued [Member] | Employees [Member]

Equity Incentive Plan description

vest at 20% per year for 5 years with an exercise price of $5.321 and an expiration date of May 1, 2034

Value of options issued

$ 131

Issuances of options for employment incentive

25,000

Stock Options Assumed in Merger [Member]

Options to purchase

75,365

Stock-based compensation

$ 1,100

Purchase price consideration

$ 3,400

Employee Benefit Plan (Details

Employee Benefit Plan (Details Narrative)	9 Months Ended
	Sep. 30, 2024
Second Contribution [Member]
Employer matching contribution, maximum (percentage)	4%
Second Contribution [Member] | Maximum [Member]
Maximum contribution per employee (percentage)	50%
Second Contribution [Member] | Minimum [Member]
Maximum contribution per employee (percentage)	3%
First Contribution [Member]
Maximum contribution per employee (percentage)	3%
Employer matching contribution, maximum (percentage)	100%
Third Contribution [Member]
Maximum contribution per employee (percentage)	5%

Related Parties (Details)

Related Parties (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($)
David Jenkins [Member]
Issuance Date	5/30/2024
Principal Amount	$ 500
Interest Paid	10
Interest Accrued	$ 5
FatBoy Capital [Member]
Issuance Date	6/25/2024
Principal Amount	$ 150
Interest Paid	2
Interest Accrued	$ 2
FatBoy Capital One [Member]
Issuance Date	7/1/2024
Principal Amount	$ 250
Interest Paid	3
Interest Accrued	$ 3
FatBoy Capital Two [Member]
Issuance Date	7/18/2024
Principal Amount	$ 100
Interest Paid	1
Interest Accrued	$ 1
Jenkins Family Charitable Institute [Member]
Issuance Date	7/25/2024
Interest Paid	$ 4
Interest Accrued	5
Principal Amount	$ 500

Related Parties (Details narrat

Related Parties (Details narrative) - USD ($)			1 Months Ended			3 Months Ended	9 Months Ended
	Sep. 03, 2024	Jan. 09, 2023	Aug. 23, 2024	Jan. 31, 2024	Mar. 21, 2023	Sep. 30, 2024	Sep. 30, 2024
Business Combination, Description		Mr. Jenkins and his affiliates received 1,325.838 shares of Series X Convertible Preferred Stock in the merger, and Mr. Jenkins’ adult children received 1,284.344 shares of Series X Convertible Preferred Stock in the merger, all in exchange for their equity interests in Old Catheter in accordance with the merger exchange ratio
Convertible Promissory Notes		$ 25,100,000
Convertible Notes		7,856
Interest accrued		$ 13,900,000
Accrued expenses		$ 1,400,000
Options to purchase		14,416
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights	$ 0.0001
Series H Warrants [Member]
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights	1
Series I Warrants [Member]
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights	1
Series J Warrants [Member]
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights	$ 1
Chief Commercial Officer [Member] | May 01, 2024 [Member]
Received options to purchase common stock							25,000
Option exercise price							$ 5.321
Vested percentage							20%
Vested period							5 years
Expiration period							expire in May 2034
Margrit Thomassen [Member]
Received options to purchase common stock				2,500			1,676
Option exercise price				$ 4			$ 5.90
Vested percentage				20%
Vested period				5 years
Expiration period				expire in January 2034
Mr. Jenkins [Member] | Pre-Funded Warrants
Interest rate	8%		12%
Maturity date			Jan. 31, 2026			Aug. 30, 2024
Warrants issued	265,000				99,182
Accrued expenses		$ 1,100,000
Options to purchase		14,416
Public offering	$ 500,000
Number of options		14,081
Remaining number of options		335
Conversion of stock description					conversion of 991.828 shares of Series X Convertible Preferred Stock, and 23,532 shares of common stock to his adult children upon conversion of 235.320 shares of Series X Convertible Preferred Stock
Exercise price		$ 5.90
Remaining number of options exercise price		$ 20.20
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights	$ 0.0001
Pre-Funded Warrant Units Issued	235,000
Mr. Jenkins [Member] | Series H Warrants [Member]
Expiration period	expire on March 3, 2025
Warrants issued	500,000
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights	$ 1
Mr. Jenkins [Member] | Series I Warrants [Member]
Expiration period	expire on March 3, 2026
Warrants issued	500,000
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights	$ 1
Mr. Jenkins [Member] | Series J Warrants [Member]
Expiration period	expire on September 3, 2029
Warrants issued	500,000
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights	$ 1

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)		1 Months Ended			9 Months Ended
	Oct. 04, 2024	Oct. 29, 2024	Oct. 21, 2024	Oct. 16, 2024	Sep. 30, 2024	Sep. 30, 2023
Proceeds					$ 0	$ 1,326,000
Subsequent Event [Member] | Pre-Funded Warrant [Member]
Exercise Date	Oct. 03, 2024
Issue Date	Oct. 04, 2024
Shares Common Stock Issued	250,000
Number of Warrants Exercised	250,000
Proceeds	$ 0
Subsequent Event [Member] | Pre-Funded Warrant One [Member]
Exercise Date				Oct. 16, 2024
Issue Date				Oct. 16, 2024
Shares Common Stock Issued				196,000
Number of Warrants Exercised				196,000
Proceeds				$ 0
Subsequent Event [Member] | Pre-Funded Warrant Two [Member]
Exercise Date			Oct. 18, 2024
Issue Date			Oct. 21, 2024
Shares Common Stock Issued			434,000
Number of Warrants Exercised			434,000
Proceeds			$ 0
Subsequent Event [Member] | Series H Warrant [Member]
Exercise Date			Oct. 18, 2024
Issue Date			Oct. 21, 2024
Shares Common Stock Issued			1,010,000
Number of Warrants Exercised			1,010,000
Proceeds			$ 1,010,000
Subsequent Event [Member] | Series I Warrant [Member]
Exercise Date			Oct. 18, 2024
Issue Date			Oct. 21, 2024
Shares Common Stock Issued			175,000
Number of Warrants Exercised			175,000
Proceeds			$ 175,000
Subsequent Event [Member] | Pre-Funded Warrant Three [Member]
Exercise Date		Oct. 29, 2024
Issue Date		Oct. 29, 2024
Shares Common Stock Issued		235,000
Number of Warrants Exercised		235,000
Proceeds		$ 0

Subsequent Events (Details narr

Subsequent Events (Details narrative) - Subsequent Event [Member] $ / shares in Units, $ in Millions	1 Months Ended
	Oct. 24, 2024 USD ($) $ / shares shares
Reverse stock split description	(i) 33,160.8 Series E Warrants, (ii) 499,909.34 Series F Warrants, (iii) 499,909.34 Series G Warrants, (iv) 1,990,000 Series H Warrants, and (v) 2,325,000 Series I Warrants to purchase up to 5.3 million shares of Common Stock at a reduced exercise price of $0.70 per share
Series H Warrants [Member]
Warrants remained outstanding after inducement offer	578,900
Series I Warrants [Member]
Warrants remained outstanding after inducement offer	1,078,900
Series K Warrants [Member]
Exercise price | $ / shares	$ 0.70
Placement agent warrants description	the company issued placement agent warrants to purchase up to 320,879 shares of common stock on the same terms as the Series K warrants, except the exercise price is $1.085 per share and have a termination date of October 28, 2029
Warrants Term description	a term of 5.5 years
Gross proceeds from warrants | $	$ 3.7
Agent fees and offering expenses | $	$ 0.4
Maximum [Member]
Exercise price | $ / shares	$ 40
2024 Inducement Offer [Member]
Gross proceeds from warrants | $	$ 1.2
2024 Inducement Offer [Member] | Series H Warrants [Member]
Warrants exercised	1,010,000
2024 Inducement Offer [Member] | Series I Warrants [Member]
Warrants exercised	175,000
Minimum [Member]
Exercise price | $ / shares	$ 1